TY  - JOUR
AU  - Lukić, Nikola
AU  - Mačvanin, Mirjana T.
AU  - Gluvić, Zoran
AU  - Rizzo, Manfredi
AU  - Radak, Đorđe
AU  - Suri, Jasjit S.
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12022
AB  - Type 2 diabetes mellitus (T2DM) has become a worldwide concern in recent years, primarily in highly developed Western societies. T2DM causes systemic complications, such as atherosclerotic heart disease, ischemic stroke, peripheral artery disease, kidney failure, and diabetes-related maculopathy and retinopathy. The growing number of T2DM patients and the treatment of long-term T2DM-related complications pressurize and exhaust public healthcare systems. As a result, strategies for combating T2DM and developing novel drugs are critical global public health requirements. Aside from preventive measures, which are still the most effective way to prevent T2DM, novel and highly effective therapies are emerging. In the spotlight of next-generation T2DM treatment, sodium-glucose co-transporter 2 (SGLT-2) inhibitors are promoted as the most efficient perspective therapy. SGLT-2 inhibitors (SGLT2i) include phlorizin derivatives, such as canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. SGLT-2, along with SGLT-1, is a member of the SGLT family of proteins that play a role in glucose absorption via active transport mediated by Na+ /K+ ATPase. SGLT-2 is only found in the kidney, specifically the proximal tubule, and is responsible for more than 90% glucose absorption. Inhibition of SGLT-2 reduces glucose absorption, and consequently increases urinary glucose excretion, decreasing blood glucose levels. Thus, the inhibition of SGLT-2 activity ultimately alleviates T2DM-related symptoms and prevents or delays systemic T2DM-associated chronic complications. This review aimed to provide a more detailed understanding of the effects of SGLT2i responsible for the acute improvement in blood glucose regulation, a prerequisite for T2DM-associated cardiovascular complications control.
T2  - Current Medicinal Chemistry
T1  - SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus
VL  - 31
DO  - 10.2174/0109298673251493231011192520
ER  - 

@article{
author = "Lukić, Nikola and Mačvanin, Mirjana T. and Gluvić, Zoran and Rizzo, Manfredi and Radak, Đorđe and Suri, Jasjit S. and Isenović, Esma R.",
year = "2023",
abstract = "Type 2 diabetes mellitus (T2DM) has become a worldwide concern in recent years, primarily in highly developed Western societies. T2DM causes systemic complications, such as atherosclerotic heart disease, ischemic stroke, peripheral artery disease, kidney failure, and diabetes-related maculopathy and retinopathy. The growing number of T2DM patients and the treatment of long-term T2DM-related complications pressurize and exhaust public healthcare systems. As a result, strategies for combating T2DM and developing novel drugs are critical global public health requirements. Aside from preventive measures, which are still the most effective way to prevent T2DM, novel and highly effective therapies are emerging. In the spotlight of next-generation T2DM treatment, sodium-glucose co-transporter 2 (SGLT-2) inhibitors are promoted as the most efficient perspective therapy. SGLT-2 inhibitors (SGLT2i) include phlorizin derivatives, such as canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. SGLT-2, along with SGLT-1, is a member of the SGLT family of proteins that play a role in glucose absorption via active transport mediated by Na+ /K+ ATPase. SGLT-2 is only found in the kidney, specifically the proximal tubule, and is responsible for more than 90% glucose absorption. Inhibition of SGLT-2 reduces glucose absorption, and consequently increases urinary glucose excretion, decreasing blood glucose levels. Thus, the inhibition of SGLT-2 activity ultimately alleviates T2DM-related symptoms and prevents or delays systemic T2DM-associated chronic complications. This review aimed to provide a more detailed understanding of the effects of SGLT2i responsible for the acute improvement in blood glucose regulation, a prerequisite for T2DM-associated cardiovascular complications control.",
journal = "Current Medicinal Chemistry",
title = "SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus",
volume = "31",
doi = "10.2174/0109298673251493231011192520"
}

Lukić, N., Mačvanin, M. T., Gluvić, Z., Rizzo, M., Radak, Đ., Suri, J. S.,& Isenović, E. R.. (2023). SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus. in Current Medicinal Chemistry, 31.
https://doi.org/10.2174/0109298673251493231011192520

Lukić N, Mačvanin MT, Gluvić Z, Rizzo M, Radak Đ, Suri JS, Isenović ER. SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus. in Current Medicinal Chemistry. 2023;31.
doi:10.2174/0109298673251493231011192520 .

Lukić, Nikola, Mačvanin, Mirjana T., Gluvić, Zoran, Rizzo, Manfredi, Radak, Đorđe, Suri, Jasjit S., Isenović, Esma R., "SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus" in Current Medicinal Chemistry, 31 (2023),
https://doi.org/10.2174/0109298673251493231011192520 . .

TY  - JOUR
AU  - Mačvanin, Mirjana
AU  - Gluvić, Zoran
AU  - Klisić, Aleksandra
AU  - Manojlović, Mia
AU  - Suri, Jasjit
AU  - Rizzo, Manfredi
AU  - Isenović, Esma
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12021
AB  - Cardiovascular disease (CDV) represents the major cause of death globally. Atherosclerosis, as the primary cause of CVD, is a chronic immune-inflammatory disorder with complex multifactorial pathophysiology encompassing oxidative stress, enhanced immune-inflammatory cascade, endothelial dysfunction, and thrombosis. An initiating event in atherosclerosis is the subendothelial accumulation of low-density lipoprotein (LDL), followed by the localization of macrophages to fatty deposits on blood vessel walls, forming lipid-laden macrophages (foam cells) that secrete compounds involved in plaque formation. Given the fact that foam cells are one of the key culprits that underlie the pathophysiology of atherosclerosis, special attention has been paid to the investigation of the efficient therapeutic approach to overcome the dysregulation of metabolism of cholesterol in macrophages, decrease the foam cell formation and/or to force its degradation. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine proteinase that has emerged as a significant regulator of the lipid metabolism pathway. PCSK9 activation leads to the degradation of LDL receptors (LDLRs), increasing LDL cholesterol (LDL-C) levels in the circulation. PCSK9 pathway dysregulation has been identified as one of the mechanisms involved in atherosclerosis. In addition, microRNAs (miRNAs) are investigated as important epigenetic factors in the pathophysiology of atherosclerosis and dysregulation of lipid metabolism. This review article summarizes the recent findings connecting the role of PCSK9 in atherosclerosis and the involvement of various miRNAs in regulating the expression of PCSK9-related genes. We also discuss PCSK9 pathway-targeting therapeutic interventions based on PCSK9 inhibition, miRNA levels manipulation by therapeutic agents, and the most recent advances in PSCK9 gene editing using CRISPR/Cas9 platform, meganuclease, and base editors.
T2  - Current Medicinal Chemistry
T1  - The Link between miRNAs and PCKS9 in Atherosclerosis
VL  - 31
DO  - 10.2174/0109298673262124231102042914
ER  - 

@article{
author = "Mačvanin, Mirjana and Gluvić, Zoran and Klisić, Aleksandra and Manojlović, Mia and Suri, Jasjit and Rizzo, Manfredi and Isenović, Esma",
year = "2023",
abstract = "Cardiovascular disease (CDV) represents the major cause of death globally. Atherosclerosis, as the primary cause of CVD, is a chronic immune-inflammatory disorder with complex multifactorial pathophysiology encompassing oxidative stress, enhanced immune-inflammatory cascade, endothelial dysfunction, and thrombosis. An initiating event in atherosclerosis is the subendothelial accumulation of low-density lipoprotein (LDL), followed by the localization of macrophages to fatty deposits on blood vessel walls, forming lipid-laden macrophages (foam cells) that secrete compounds involved in plaque formation. Given the fact that foam cells are one of the key culprits that underlie the pathophysiology of atherosclerosis, special attention has been paid to the investigation of the efficient therapeutic approach to overcome the dysregulation of metabolism of cholesterol in macrophages, decrease the foam cell formation and/or to force its degradation. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine proteinase that has emerged as a significant regulator of the lipid metabolism pathway. PCSK9 activation leads to the degradation of LDL receptors (LDLRs), increasing LDL cholesterol (LDL-C) levels in the circulation. PCSK9 pathway dysregulation has been identified as one of the mechanisms involved in atherosclerosis. In addition, microRNAs (miRNAs) are investigated as important epigenetic factors in the pathophysiology of atherosclerosis and dysregulation of lipid metabolism. This review article summarizes the recent findings connecting the role of PCSK9 in atherosclerosis and the involvement of various miRNAs in regulating the expression of PCSK9-related genes. We also discuss PCSK9 pathway-targeting therapeutic interventions based on PCSK9 inhibition, miRNA levels manipulation by therapeutic agents, and the most recent advances in PSCK9 gene editing using CRISPR/Cas9 platform, meganuclease, and base editors.",
journal = "Current Medicinal Chemistry",
title = "The Link between miRNAs and PCKS9 in Atherosclerosis",
volume = "31",
doi = "10.2174/0109298673262124231102042914"
}

Mačvanin, M., Gluvić, Z., Klisić, A., Manojlović, M., Suri, J., Rizzo, M.,& Isenović, E.. (2023). The Link between miRNAs and PCKS9 in Atherosclerosis. in Current Medicinal Chemistry, 31.
https://doi.org/10.2174/0109298673262124231102042914

Mačvanin M, Gluvić Z, Klisić A, Manojlović M, Suri J, Rizzo M, Isenović E. The Link between miRNAs and PCKS9 in Atherosclerosis. in Current Medicinal Chemistry. 2023;31.
doi:10.2174/0109298673262124231102042914 .

Mačvanin, Mirjana, Gluvić, Zoran, Klisić, Aleksandra, Manojlović, Mia, Suri, Jasjit, Rizzo, Manfredi, Isenović, Esma, "The Link between miRNAs and PCKS9 in Atherosclerosis" in Current Medicinal Chemistry, 31 (2023),
https://doi.org/10.2174/0109298673262124231102042914 . .

TY  - JOUR
AU  - Gluvić, Zoran
AU  - Zafirović, Sonja
AU  - Obradović, Milan M.
AU  - Sudar-Milovanović, Emina
AU  - Rizzo, Manfredi
AU  - Isenović, Esma R.
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10409
AB  - Thyroid hormones (TH) have a significant impact on cellular oxidative metabolism. Besides that,they maintain vascular homeostasis by positive effects on endothelial and vascular smooth muscle cells. Subclinical(SCH) and clinical (CH) hypothyroidism influences target organs by changing their morphology andfunction and impaired blood and oxygen supply induced by accelerated atherosclerosis. The increased risk ofacceleration and extension of atherosclerosis in patients with SCH and CH could be explained by dyslipidemia,diastolic hypertension, increased arterial stiffness, endothelial dysfunction, and altered blood coagulation. Instabilityof atherosclerotic plaque in hypothyroidism could cause excessive activity of the elements of innateimmunity, which are characterized by the significant presence of macrophages in atherosclerotic plaques, increasednuclear factor kappa B (NFkB) expression, and elevated levels of tumor necrosis factor α (TNF-α) andmatrix metalloproteinase (MMP) 9, with reduced interstitial collagen; all of them together creates inflammationmilieu, resulting in plaque rupture. Optimal substitution by levothyroxine (LT4) restores biochemical euthyroidism.In postmenopausal women and elderly patients with hypothyroidism and associated vascularcomorbidity, excessive LT4 substitution could lead to atrial rhythm disorders and osteoporosis. Therefore, it isof interest to maintain thyroid-stimulating hormone (TSH) levels in the reference range, thus eliminating thedeleterious effects of lower or higher TSH levels on the cardiovascular system. This review summarizes the recentliterature on subclinical and clinical hypothyroidism and atherosclerotic cardiovascular disease and discussesthe effects of LT4 replacement therapy on restoring biochemical euthyroidism and atherosclerosis processes.
T2  - Current Pharmaceutical Design
T1  - Hypothyroidism and Risk of Cardiovascular Disease
VL  - 28
IS  - 25
SP  - 2065
EP  - 2072
DO  - 10.2174/1381612828666220620160516
ER  - 

@article{
author = "Gluvić, Zoran and Zafirović, Sonja and Obradović, Milan M. and Sudar-Milovanović, Emina and Rizzo, Manfredi and Isenović, Esma R.",
year = "2022",
abstract = "Thyroid hormones (TH) have a significant impact on cellular oxidative metabolism. Besides that,they maintain vascular homeostasis by positive effects on endothelial and vascular smooth muscle cells. Subclinical(SCH) and clinical (CH) hypothyroidism influences target organs by changing their morphology andfunction and impaired blood and oxygen supply induced by accelerated atherosclerosis. The increased risk ofacceleration and extension of atherosclerosis in patients with SCH and CH could be explained by dyslipidemia,diastolic hypertension, increased arterial stiffness, endothelial dysfunction, and altered blood coagulation. Instabilityof atherosclerotic plaque in hypothyroidism could cause excessive activity of the elements of innateimmunity, which are characterized by the significant presence of macrophages in atherosclerotic plaques, increasednuclear factor kappa B (NFkB) expression, and elevated levels of tumor necrosis factor α (TNF-α) andmatrix metalloproteinase (MMP) 9, with reduced interstitial collagen; all of them together creates inflammationmilieu, resulting in plaque rupture. Optimal substitution by levothyroxine (LT4) restores biochemical euthyroidism.In postmenopausal women and elderly patients with hypothyroidism and associated vascularcomorbidity, excessive LT4 substitution could lead to atrial rhythm disorders and osteoporosis. Therefore, it isof interest to maintain thyroid-stimulating hormone (TSH) levels in the reference range, thus eliminating thedeleterious effects of lower or higher TSH levels on the cardiovascular system. This review summarizes the recentliterature on subclinical and clinical hypothyroidism and atherosclerotic cardiovascular disease and discussesthe effects of LT4 replacement therapy on restoring biochemical euthyroidism and atherosclerosis processes.",
journal = "Current Pharmaceutical Design",
title = "Hypothyroidism and Risk of Cardiovascular Disease",
volume = "28",
number = "25",
pages = "2065-2072",
doi = "10.2174/1381612828666220620160516"
}

Gluvić, Z., Zafirović, S., Obradović, M. M., Sudar-Milovanović, E., Rizzo, M.,& Isenović, E. R.. (2022). Hypothyroidism and Risk of Cardiovascular Disease. in Current Pharmaceutical Design, 28(25), 2065-2072.
https://doi.org/10.2174/1381612828666220620160516

Gluvić Z, Zafirović S, Obradović MM, Sudar-Milovanović E, Rizzo M, Isenović ER. Hypothyroidism and Risk of Cardiovascular Disease. in Current Pharmaceutical Design. 2022;28(25):2065-2072.
doi:10.2174/1381612828666220620160516 .

Gluvić, Zoran, Zafirović, Sonja, Obradović, Milan M., Sudar-Milovanović, Emina, Rizzo, Manfredi, Isenović, Esma R., "Hypothyroidism and Risk of Cardiovascular Disease" in Current Pharmaceutical Design, 28, no. 25 (2022):2065-2072,
https://doi.org/10.2174/1381612828666220620160516 . .

TY  - JOUR
AU  - Sudar-Milovanović, Emina
AU  - Gluvić, Zoran
AU  - Obradović, Milan M.
AU  - Zarić, Božidarka
AU  - Isenović, Esma R.
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10147
AB  - The essential amino acid tryptophan (Trp) undergoes catabolism through several pathways, producing biologically active metabolites that significantly impact physiological processes. The metabolic pathway responsible for the majority of Trp catabolism is the kynurenine synthesis pathway (KP). Serotonin and melatonin are among the most essential Trp pathways degradation products. It has emerged that a strong relationship exists between alterations in Trp metabolism and the onset and progression of atherosclerosis and diabetes. Atherosclerosis is a chronic inflammatory disease of the small and medium arteries wall caused by maladaptive local immune responses, which underpins several cardiovascular diseases (CVD). Systemic low-grade immune-mediated inflammation is implicated in atherosclerosis where pro-inflammatory cytokines, such as interferon-γ (IFN-γ), play a significant role. IFN-γ upregulates the enzyme indoleamine 2,3-dioxygenase (IDO), decreasing serum levels of the Trp and increasing metabolite levels of kynurenine. Increased IDO expression and activity could accelerate the atherosclerosis process. Therefore, activated IDO inhibition could offer possible treatment options regarding atherosclerosis management. Diabetes is a chronic metabolic disease characterized by hyperglycemia that, over time, leads to severe damage to the heart, blood vessels, eyes, kidneys, and peripheral nerves. Trp serum levels and lower activity of IDO were higher in future type 2 diabetes (T2DM) patients. This article reviews recent findings on the link between mammalian Trp metabolism and its role in atherosclerosis and diabetes and outlines the intervention strategies.
T2  - Current Medicinal Chemistry
T1  - Tryptophan Metabolism in Atherosclerosis and Diabetes
VL  - 29
IS  - 1
SP  - 99
EP  - 113
DO  - 10.2174/0929867328666210714153649
ER  - 

@article{
author = "Sudar-Milovanović, Emina and Gluvić, Zoran and Obradović, Milan M. and Zarić, Božidarka and Isenović, Esma R.",
year = "2022",
abstract = "The essential amino acid tryptophan (Trp) undergoes catabolism through several pathways, producing biologically active metabolites that significantly impact physiological processes. The metabolic pathway responsible for the majority of Trp catabolism is the kynurenine synthesis pathway (KP). Serotonin and melatonin are among the most essential Trp pathways degradation products. It has emerged that a strong relationship exists between alterations in Trp metabolism and the onset and progression of atherosclerosis and diabetes. Atherosclerosis is a chronic inflammatory disease of the small and medium arteries wall caused by maladaptive local immune responses, which underpins several cardiovascular diseases (CVD). Systemic low-grade immune-mediated inflammation is implicated in atherosclerosis where pro-inflammatory cytokines, such as interferon-γ (IFN-γ), play a significant role. IFN-γ upregulates the enzyme indoleamine 2,3-dioxygenase (IDO), decreasing serum levels of the Trp and increasing metabolite levels of kynurenine. Increased IDO expression and activity could accelerate the atherosclerosis process. Therefore, activated IDO inhibition could offer possible treatment options regarding atherosclerosis management. Diabetes is a chronic metabolic disease characterized by hyperglycemia that, over time, leads to severe damage to the heart, blood vessels, eyes, kidneys, and peripheral nerves. Trp serum levels and lower activity of IDO were higher in future type 2 diabetes (T2DM) patients. This article reviews recent findings on the link between mammalian Trp metabolism and its role in atherosclerosis and diabetes and outlines the intervention strategies.",
journal = "Current Medicinal Chemistry",
title = "Tryptophan Metabolism in Atherosclerosis and Diabetes",
volume = "29",
number = "1",
pages = "99-113",
doi = "10.2174/0929867328666210714153649"
}

Sudar-Milovanović, E., Gluvić, Z., Obradović, M. M., Zarić, B.,& Isenović, E. R.. (2022). Tryptophan Metabolism in Atherosclerosis and Diabetes. in Current Medicinal Chemistry, 29(1), 99-113.
https://doi.org/10.2174/0929867328666210714153649

Sudar-Milovanović E, Gluvić Z, Obradović MM, Zarić B, Isenović ER. Tryptophan Metabolism in Atherosclerosis and Diabetes. in Current Medicinal Chemistry. 2022;29(1):99-113.
doi:10.2174/0929867328666210714153649 .

Sudar-Milovanović, Emina, Gluvić, Zoran, Obradović, Milan M., Zarić, Božidarka, Isenović, Esma R., "Tryptophan Metabolism in Atherosclerosis and Diabetes" in Current Medicinal Chemistry, 29, no. 1 (2022):99-113,
https://doi.org/10.2174/0929867328666210714153649 . .

TY  - JOUR
AU  - Stanimirović, Julijana
AU  - Radovanović, Jelena
AU  - Banjac, Katarina
AU  - Obradović, Milan M.
AU  - Essack, Magbubah
AU  - Zafirović, Sonja
AU  - Gluvić, Zoran
AU  - Gojobori, Takashi
AU  - Isenović, Esma R.
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10285
AB  - Even though type 2 diabetes mellitus (T2DM) represents a worldwide chronic health issue that affects about 462 million people, specific underlying determinants of insulin resistance (IR) and impaired insulin secretion are still unknown. There is growing evidence that chronic subclinical inflammation is a triggering factor in the origin of T2DM. Increased C-reactive protein (CRP) levels have been linked to excess body weight since adipocytes produce tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), which are pivotal factors for CRP stimulation. Furthermore, it is known that hepatocytes produce relatively low rates of CRP in physiological conditions compared to T2DM patients, in which elevated levels of inflammatory markers are reported, including CRP. CRP also participates in endothelial dysfunction, the production of vasodilators, and vascular remodeling, and increased CRP level is closely associated with vascular system pathology and metabolic syndrome. In addition, insulin-based therapies may alter CRP levels in T2DM. Therefore, determining and clarifying the underlying CRP mechanism of T2DM is imperative for novel preventive and diagnostic procedures. Overall, CRP is one of the possible targets for T2DM progression and understanding the connection between insulin and inflammation may be helpful in clinical treatment and prevention approaches.
T2  - Mediators of Inflammation
T1  - Role of C-Reactive Protein in Diabetic Inflammation
VL  - 2022
SP  - e3706508
DO  - 10.1155/2022/3706508
ER  - 

@article{
author = "Stanimirović, Julijana and Radovanović, Jelena and Banjac, Katarina and Obradović, Milan M. and Essack, Magbubah and Zafirović, Sonja and Gluvić, Zoran and Gojobori, Takashi and Isenović, Esma R.",
year = "2022",
abstract = "Even though type 2 diabetes mellitus (T2DM) represents a worldwide chronic health issue that affects about 462 million people, specific underlying determinants of insulin resistance (IR) and impaired insulin secretion are still unknown. There is growing evidence that chronic subclinical inflammation is a triggering factor in the origin of T2DM. Increased C-reactive protein (CRP) levels have been linked to excess body weight since adipocytes produce tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), which are pivotal factors for CRP stimulation. Furthermore, it is known that hepatocytes produce relatively low rates of CRP in physiological conditions compared to T2DM patients, in which elevated levels of inflammatory markers are reported, including CRP. CRP also participates in endothelial dysfunction, the production of vasodilators, and vascular remodeling, and increased CRP level is closely associated with vascular system pathology and metabolic syndrome. In addition, insulin-based therapies may alter CRP levels in T2DM. Therefore, determining and clarifying the underlying CRP mechanism of T2DM is imperative for novel preventive and diagnostic procedures. Overall, CRP is one of the possible targets for T2DM progression and understanding the connection between insulin and inflammation may be helpful in clinical treatment and prevention approaches.",
journal = "Mediators of Inflammation",
title = "Role of C-Reactive Protein in Diabetic Inflammation",
volume = "2022",
pages = "e3706508",
doi = "10.1155/2022/3706508"
}

Stanimirović, J., Radovanović, J., Banjac, K., Obradović, M. M., Essack, M., Zafirović, S., Gluvić, Z., Gojobori, T.,& Isenović, E. R.. (2022). Role of C-Reactive Protein in Diabetic Inflammation. in Mediators of Inflammation, 2022, e3706508.
https://doi.org/10.1155/2022/3706508

Stanimirović J, Radovanović J, Banjac K, Obradović MM, Essack M, Zafirović S, Gluvić Z, Gojobori T, Isenović ER. Role of C-Reactive Protein in Diabetic Inflammation. in Mediators of Inflammation. 2022;2022:e3706508.
doi:10.1155/2022/3706508 .

Stanimirović, Julijana, Radovanović, Jelena, Banjac, Katarina, Obradović, Milan M., Essack, Magbubah, Zafirović, Sonja, Gluvić, Zoran, Gojobori, Takashi, Isenović, Esma R., "Role of C-Reactive Protein in Diabetic Inflammation" in Mediators of Inflammation, 2022 (2022):e3706508,
https://doi.org/10.1155/2022/3706508 . .

TY  - JOUR
AU  - Gluvić, Zoran
AU  - Obradović, Milan M.
AU  - Stewart, Alan J.
AU  - Essack, Magbubah
AU  - Pitt, Samantha J.
AU  - Samardžić, Vladimir
AU  - Soskić, Sanja S.
AU  - Gojobori, Takashi
AU  - Isenović, Esma R.
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10047
AB  - Levothyroxine (LT4) is used to treat frequently encountered endocrinopathies such as thyroid diseases. It is regularly used in clinical (overt) hypothyroidism cases and subclinical (latent) hypothyroidism cases in the last decade. Suppressive LT4 therapy is also part of the medical regimen used to manage thyroid malignancies after a thyroidectomy. LT4 treatment possesses dual effects: substituting new-onset thyroid hormone deficiency and suppressing the local and distant malignancy spreading in cancer. It is the practice to administer LT4 in less-than-high suppressive doses for growth control of thyroid nodules and goiter, even in patients with preserved thyroid function. Despite its approved safety for clinical use, LT4 can sometimes induce side-effects, more often recorded with patients under treatment with LT4 suppressive doses than in unintentionally LT4-overdosed patients. Cardiac arrhythmias and the deterioration of osteoporosis are the most frequently documented side-effects of LT4 therapy. It also lowers the threshold for the onset or aggravation of cardiac arrhythmias for patients with pre-existing heart diseases. To improve the quality of life in LT4-substituted patients, clinicians often prescribe higher doses of LT4 to reach low normal TSH levels to achieve cellular euthyroidism. In such circumstances, the risk of cardiac arrhythmias, particularly atrial fibrillation, increases, and the combined use of LT4 and triiodothyronine further complicates such risk. This review summarizes the relevant available data related to LT4 suppressive treatment and the associated risk of cardiac arrhythmia.
T2  - Frontiers in Endocrinology
T1  - Levothyroxine Treatment and the Risk of Cardiac Arrhythmias – Focus on the Patient Submitted to Thyroid Surgery
VL  - 12
SP  - 1415
DO  - 10.3389/fendo.2021.758043
ER  - 

@article{
author = "Gluvić, Zoran and Obradović, Milan M. and Stewart, Alan J. and Essack, Magbubah and Pitt, Samantha J. and Samardžić, Vladimir and Soskić, Sanja S. and Gojobori, Takashi and Isenović, Esma R.",
year = "2021",
abstract = "Levothyroxine (LT4) is used to treat frequently encountered endocrinopathies such as thyroid diseases. It is regularly used in clinical (overt) hypothyroidism cases and subclinical (latent) hypothyroidism cases in the last decade. Suppressive LT4 therapy is also part of the medical regimen used to manage thyroid malignancies after a thyroidectomy. LT4 treatment possesses dual effects: substituting new-onset thyroid hormone deficiency and suppressing the local and distant malignancy spreading in cancer. It is the practice to administer LT4 in less-than-high suppressive doses for growth control of thyroid nodules and goiter, even in patients with preserved thyroid function. Despite its approved safety for clinical use, LT4 can sometimes induce side-effects, more often recorded with patients under treatment with LT4 suppressive doses than in unintentionally LT4-overdosed patients. Cardiac arrhythmias and the deterioration of osteoporosis are the most frequently documented side-effects of LT4 therapy. It also lowers the threshold for the onset or aggravation of cardiac arrhythmias for patients with pre-existing heart diseases. To improve the quality of life in LT4-substituted patients, clinicians often prescribe higher doses of LT4 to reach low normal TSH levels to achieve cellular euthyroidism. In such circumstances, the risk of cardiac arrhythmias, particularly atrial fibrillation, increases, and the combined use of LT4 and triiodothyronine further complicates such risk. This review summarizes the relevant available data related to LT4 suppressive treatment and the associated risk of cardiac arrhythmia.",
journal = "Frontiers in Endocrinology",
title = "Levothyroxine Treatment and the Risk of Cardiac Arrhythmias – Focus on the Patient Submitted to Thyroid Surgery",
volume = "12",
pages = "1415",
doi = "10.3389/fendo.2021.758043"
}

Gluvić, Z., Obradović, M. M., Stewart, A. J., Essack, M., Pitt, S. J., Samardžić, V., Soskić, S. S., Gojobori, T.,& Isenović, E. R.. (2021). Levothyroxine Treatment and the Risk of Cardiac Arrhythmias – Focus on the Patient Submitted to Thyroid Surgery. in Frontiers in Endocrinology, 12, 1415.
https://doi.org/10.3389/fendo.2021.758043

Gluvić Z, Obradović MM, Stewart AJ, Essack M, Pitt SJ, Samardžić V, Soskić SS, Gojobori T, Isenović ER. Levothyroxine Treatment and the Risk of Cardiac Arrhythmias – Focus on the Patient Submitted to Thyroid Surgery. in Frontiers in Endocrinology. 2021;12:1415.
doi:10.3389/fendo.2021.758043 .

Gluvić, Zoran, Obradović, Milan M., Stewart, Alan J., Essack, Magbubah, Pitt, Samantha J., Samardžić, Vladimir, Soskić, Sanja S., Gojobori, Takashi, Isenović, Esma R., "Levothyroxine Treatment and the Risk of Cardiac Arrhythmias – Focus on the Patient Submitted to Thyroid Surgery" in Frontiers in Endocrinology, 12 (2021):1415,
https://doi.org/10.3389/fendo.2021.758043 . .

TY  - JOUR
AU  - Samardžić, Vladimir
AU  - Banjac, Katarina
AU  - Obradović, Milan
AU  - Gluvić, Zoran
AU  - Isenović, Esma R.
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9697
AB  - Thyroid nodules are among highly prevalent thyroid diseases. To make a distinction between benign and malignant thyroid nodules are of cumbersome significance for each endocrinologist. There is no unique and completely accurate diagnostic test, method, or even biomarker that points to a malignant thyroid nodule. Many studies in modern thyroidology are conducted to determine the usefulness of individual biomarkers, which could help clinicians detect thyroid nodules' potential malignant nature. One interesting biomarker with a promising diagnostic potential for the thyroid gland pathological conditions is nitric oxide (NO). Inducible nitric oxide synthase expression is increased in thyroiditis cases and even more in thyroid carcinoma cases, directly connected with increased NO levels in both pathological conditions. We hypothesize that the basal levels of nitrite/nitrate in serum and biopsy washout could indicate nodules' malignant nature.
T2  - Medical Hypotheses
T1  - Could the level of nitrite/nitrate contribute to malignant thyroid nodule diagnostics?
VL  - 150
SP  - 110569
DO  - 10.1016/j.mehy.2021.110569
ER  - 

@article{
author = "Samardžić, Vladimir and Banjac, Katarina and Obradović, Milan and Gluvić, Zoran and Isenović, Esma R.",
year = "2021",
abstract = "Thyroid nodules are among highly prevalent thyroid diseases. To make a distinction between benign and malignant thyroid nodules are of cumbersome significance for each endocrinologist. There is no unique and completely accurate diagnostic test, method, or even biomarker that points to a malignant thyroid nodule. Many studies in modern thyroidology are conducted to determine the usefulness of individual biomarkers, which could help clinicians detect thyroid nodules' potential malignant nature. One interesting biomarker with a promising diagnostic potential for the thyroid gland pathological conditions is nitric oxide (NO). Inducible nitric oxide synthase expression is increased in thyroiditis cases and even more in thyroid carcinoma cases, directly connected with increased NO levels in both pathological conditions. We hypothesize that the basal levels of nitrite/nitrate in serum and biopsy washout could indicate nodules' malignant nature.",
journal = "Medical Hypotheses",
title = "Could the level of nitrite/nitrate contribute to malignant thyroid nodule diagnostics?",
volume = "150",
pages = "110569",
doi = "10.1016/j.mehy.2021.110569"
}

Samardžić, V., Banjac, K., Obradović, M., Gluvić, Z.,& Isenović, E. R.. (2021). Could the level of nitrite/nitrate contribute to malignant thyroid nodule diagnostics?. in Medical Hypotheses, 150, 110569.
https://doi.org/10.1016/j.mehy.2021.110569

Samardžić V, Banjac K, Obradović M, Gluvić Z, Isenović ER. Could the level of nitrite/nitrate contribute to malignant thyroid nodule diagnostics?. in Medical Hypotheses. 2021;150:110569.
doi:10.1016/j.mehy.2021.110569 .

Samardžić, Vladimir, Banjac, Katarina, Obradović, Milan, Gluvić, Zoran, Isenović, Esma R., "Could the level of nitrite/nitrate contribute to malignant thyroid nodule diagnostics?" in Medical Hypotheses, 150 (2021):110569,
https://doi.org/10.1016/j.mehy.2021.110569 . .

TY  - JOUR
AU  - Resanović, Ivana
AU  - Zarić, Božidarka
AU  - Radovanović, Jelena V.
AU  - Sudar-Milovanović, Emina
AU  - Gluvić, Zoran
AU  - Jevremović, Danimir
AU  - Isenović, Esma R.
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9662
AB  - Vascular complications in patients with diabetes mellitus (DM) are common. Since impaired oxygen balance in plasma plays an important role in the pathogenesis of chronic DM-associated complications, the administration of hyperbaric oxygen therapy (HBOT) has been recommended to influence development of vascular complications. Hyperbaric oxygen therapy involves inhalation of 100% oxygen under elevated pressure from 1.6 to 2.8 absolute atmospheres in hyperbaric chambers. Hyperbaric oxygen therapy increases plasma oxygen solubility, contributing to better oxygen diffusion to distant tissues and preservation of the viability of tissues reversibly damaged by atherosclerosis-induced ischemia, along with microcirculation restoration. Hyperbaric oxygen therapy exerts antiatherogenic, antioxidant, and cardioprotective effects by altering the level and composition of plasma fatty acids and also by promoting signal transduction through membranes, which are impaired by hyperglycemia and hypoxia. In addition, HBOT affects molecules involved in the regulation of nitric oxide synthesis and in that way exerts anti-inflammatory and angiogenic effects in patients with DM. In this review, we explore the recent literature related to the effects of HBOT on DM-related vascular complications.
T2  - Angiology
T1  - Hyperbaric Oxygen Therapy and Vascular Complications in Diabetes Mellitus
VL  - 71
IS  - 10
SP  - 876
EP  - 885
DO  - 10.1177/0003319720936925
ER  - 

@article{
author = "Resanović, Ivana and Zarić, Božidarka and Radovanović, Jelena V. and Sudar-Milovanović, Emina and Gluvić, Zoran and Jevremović, Danimir and Isenović, Esma R.",
year = "2020",
abstract = "Vascular complications in patients with diabetes mellitus (DM) are common. Since impaired oxygen balance in plasma plays an important role in the pathogenesis of chronic DM-associated complications, the administration of hyperbaric oxygen therapy (HBOT) has been recommended to influence development of vascular complications. Hyperbaric oxygen therapy involves inhalation of 100% oxygen under elevated pressure from 1.6 to 2.8 absolute atmospheres in hyperbaric chambers. Hyperbaric oxygen therapy increases plasma oxygen solubility, contributing to better oxygen diffusion to distant tissues and preservation of the viability of tissues reversibly damaged by atherosclerosis-induced ischemia, along with microcirculation restoration. Hyperbaric oxygen therapy exerts antiatherogenic, antioxidant, and cardioprotective effects by altering the level and composition of plasma fatty acids and also by promoting signal transduction through membranes, which are impaired by hyperglycemia and hypoxia. In addition, HBOT affects molecules involved in the regulation of nitric oxide synthesis and in that way exerts anti-inflammatory and angiogenic effects in patients with DM. In this review, we explore the recent literature related to the effects of HBOT on DM-related vascular complications.",
journal = "Angiology",
title = "Hyperbaric Oxygen Therapy and Vascular Complications in Diabetes Mellitus",
volume = "71",
number = "10",
pages = "876-885",
doi = "10.1177/0003319720936925"
}

Resanović, I., Zarić, B., Radovanović, J. V., Sudar-Milovanović, E., Gluvić, Z., Jevremović, D.,& Isenović, E. R.. (2020). Hyperbaric Oxygen Therapy and Vascular Complications in Diabetes Mellitus. in Angiology, 71(10), 876-885.
https://doi.org/10.1177/0003319720936925

Resanović I, Zarić B, Radovanović JV, Sudar-Milovanović E, Gluvić Z, Jevremović D, Isenović ER. Hyperbaric Oxygen Therapy and Vascular Complications in Diabetes Mellitus. in Angiology. 2020;71(10):876-885.
doi:10.1177/0003319720936925 .

Resanović, Ivana, Zarić, Božidarka, Radovanović, Jelena V., Sudar-Milovanović, Emina, Gluvić, Zoran, Jevremović, Danimir, Isenović, Esma R., "Hyperbaric Oxygen Therapy and Vascular Complications in Diabetes Mellitus" in Angiology, 71, no. 10 (2020):876-885,
https://doi.org/10.1177/0003319720936925 . .

TY  - JOUR
AU  - Gluvić, Zoran
AU  - Obradović, Milan M.
AU  - Sudar-Milovanović, Emina
AU  - Zafirović, Sonja
AU  - Radak, Đorđe J.
AU  - Essack, Magbubah
AU  - Bajić, Vladimir B.
AU  - Gojobori, Takashi
AU  - Isenović, Esma R.
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8474
AB  - Hypothyroidism is a common endocrine disorder that predominantly occurs in females. It is associated with an increased risk of cardiovascular diseases (CVD), but the molecular mechanism is not known. Disturbance in lipid metabolism, the regulation of oxidative stress, and inflammation characterize the progression of subclinical hypothyroidism. The initiation and progression of endothelial dysfunction also exhibit these changes, which is the initial step in developing CVD. Animal and human studies highlight the critical role of nitric oxide (NO) as a reliable biomarker for cardiovascular risk in subclinical and clinical hypothyroidism. In this review, we summarize the recent literature findings associated with NO production by the thyroid hormones in both physiological and pathophysiological conditions. We also discuss the levothyroxine treatment effect on serum NO levels in hypothyroid patients. © 2020 The Authors
T2  - Biomedicine and Pharmacotherapy
T1  - Regulation of nitric oxide production in hypothyroidism
VL  - 124
SP  - 109881
DO  - 10.1016/j.biopha.2020.109881
ER  - 

@article{
author = "Gluvić, Zoran and Obradović, Milan M. and Sudar-Milovanović, Emina and Zafirović, Sonja and Radak, Đorđe J. and Essack, Magbubah and Bajić, Vladimir B. and Gojobori, Takashi and Isenović, Esma R.",
year = "2020",
abstract = "Hypothyroidism is a common endocrine disorder that predominantly occurs in females. It is associated with an increased risk of cardiovascular diseases (CVD), but the molecular mechanism is not known. Disturbance in lipid metabolism, the regulation of oxidative stress, and inflammation characterize the progression of subclinical hypothyroidism. The initiation and progression of endothelial dysfunction also exhibit these changes, which is the initial step in developing CVD. Animal and human studies highlight the critical role of nitric oxide (NO) as a reliable biomarker for cardiovascular risk in subclinical and clinical hypothyroidism. In this review, we summarize the recent literature findings associated with NO production by the thyroid hormones in both physiological and pathophysiological conditions. We also discuss the levothyroxine treatment effect on serum NO levels in hypothyroid patients. © 2020 The Authors",
journal = "Biomedicine and Pharmacotherapy",
title = "Regulation of nitric oxide production in hypothyroidism",
volume = "124",
pages = "109881",
doi = "10.1016/j.biopha.2020.109881"
}

Gluvić, Z., Obradović, M. M., Sudar-Milovanović, E., Zafirović, S., Radak, Đ. J., Essack, M., Bajić, V. B., Gojobori, T.,& Isenović, E. R.. (2020). Regulation of nitric oxide production in hypothyroidism. in Biomedicine and Pharmacotherapy, 124, 109881.
https://doi.org/10.1016/j.biopha.2020.109881

Gluvić Z, Obradović MM, Sudar-Milovanović E, Zafirović S, Radak ĐJ, Essack M, Bajić VB, Gojobori T, Isenović ER. Regulation of nitric oxide production in hypothyroidism. in Biomedicine and Pharmacotherapy. 2020;124:109881.
doi:10.1016/j.biopha.2020.109881 .

Gluvić, Zoran, Obradović, Milan M., Sudar-Milovanović, Emina, Zafirović, Sonja, Radak, Đorđe J., Essack, Magbubah, Bajić, Vladimir B., Gojobori, Takashi, Isenović, Esma R., "Regulation of nitric oxide production in hypothyroidism" in Biomedicine and Pharmacotherapy, 124 (2020):109881,
https://doi.org/10.1016/j.biopha.2020.109881 . .

TY  - JOUR
AU  - Resanović, Ivana
AU  - Gluvić, Zoran
AU  - Zarić, Božidarka
AU  - Sudar-Milovanović, Emina
AU  - Vučić, Vesna
AU  - Arsić, Aleksandra
AU  - Nedić, Olgica
AU  - Šunderić, Miloš
AU  - Gligorijević, Nikola
AU  - Milačić, Davorka
AU  - Isenović, Esma R.
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8567
AB  - Objective: Metabolic changes in insulin-dependent diabetes mellitus (IDDM) impair vasodilation, and this leads to tissue hypoxia and microvascular pathology. Hyperbaric oxygen therapy (HBOT) can significantly improve the outcome of ischemic conditions in IDDM patients and reduce vascular complications. The aim of our study was to assess the effects of HBOT on plasma fatty acid (FA) composition, and expression of insulin-like growth factor binding protein 1 (IGFBP-1) in IDDM patients. Methods: Our study included 24 adult IDDM patients diagnosed with peripheral vascular complications. The patients were exposed to 10 sessions of 100% oxygen inhalation at 2.4 atmosphere absolute for 1 hour. Blood samples were collected at admission and after HBOT for measurement of metabolic parameters, FA composition and IGFBP-1. Measurement of plasma FA composition was determined by gas chromatography. Expression of IGFBP-1 in the serum was estimated by Western blot analysis. Results: HBOT decreased blood levels of total cholesterol (p<0.05), triglycerides (p<0.05) and low-density lipoprotein (p<0.05). HBOT increased plasma levels of individual FAs: palmitic acid (p<0.05), palmitoleic acid (p<0.05), docosapentaenoic acid (p<0.05) and docosahexaenoic acid (p<0.01), and decreased levels of stearic acid (p<0.05), alpha linolenic acid (p<0.05) and linoleic acid (p<0.01). Expression of IGFBP-1 (p<0.01) was increased, whereas the level of insulin (p<0.001) was decreased in the serum after HBOT. Conclusions: Our results indicate that HBOT exerts beneficial effects in IDDM patients by improving the lipid profile and altering FA composition. © 2019 Canadian Diabetes Association
T2  - Canadian Journal of Diabetes
T1  - Effect of Hyperbaric Oxygen Therapy on Fatty Acid Composition and Insulin-like Growth Factor Binding Protein 1 in Adult Type 1 Diabetes Mellitus Patients: A Pilot Study
VL  - 44
IS  - 1
SP  - 22
EP  - 29
DO  - 10.1016/j.jcjd.2019.04.018
ER  - 

@article{
author = "Resanović, Ivana and Gluvić, Zoran and Zarić, Božidarka and Sudar-Milovanović, Emina and Vučić, Vesna and Arsić, Aleksandra and Nedić, Olgica and Šunderić, Miloš and Gligorijević, Nikola and Milačić, Davorka and Isenović, Esma R.",
year = "2020",
abstract = "Objective: Metabolic changes in insulin-dependent diabetes mellitus (IDDM) impair vasodilation, and this leads to tissue hypoxia and microvascular pathology. Hyperbaric oxygen therapy (HBOT) can significantly improve the outcome of ischemic conditions in IDDM patients and reduce vascular complications. The aim of our study was to assess the effects of HBOT on plasma fatty acid (FA) composition, and expression of insulin-like growth factor binding protein 1 (IGFBP-1) in IDDM patients. Methods: Our study included 24 adult IDDM patients diagnosed with peripheral vascular complications. The patients were exposed to 10 sessions of 100% oxygen inhalation at 2.4 atmosphere absolute for 1 hour. Blood samples were collected at admission and after HBOT for measurement of metabolic parameters, FA composition and IGFBP-1. Measurement of plasma FA composition was determined by gas chromatography. Expression of IGFBP-1 in the serum was estimated by Western blot analysis. Results: HBOT decreased blood levels of total cholesterol (p<0.05), triglycerides (p<0.05) and low-density lipoprotein (p<0.05). HBOT increased plasma levels of individual FAs: palmitic acid (p<0.05), palmitoleic acid (p<0.05), docosapentaenoic acid (p<0.05) and docosahexaenoic acid (p<0.01), and decreased levels of stearic acid (p<0.05), alpha linolenic acid (p<0.05) and linoleic acid (p<0.01). Expression of IGFBP-1 (p<0.01) was increased, whereas the level of insulin (p<0.001) was decreased in the serum after HBOT. Conclusions: Our results indicate that HBOT exerts beneficial effects in IDDM patients by improving the lipid profile and altering FA composition. © 2019 Canadian Diabetes Association",
journal = "Canadian Journal of Diabetes",
title = "Effect of Hyperbaric Oxygen Therapy on Fatty Acid Composition and Insulin-like Growth Factor Binding Protein 1 in Adult Type 1 Diabetes Mellitus Patients: A Pilot Study",
volume = "44",
number = "1",
pages = "22-29",
doi = "10.1016/j.jcjd.2019.04.018"
}

Resanović, I., Gluvić, Z., Zarić, B., Sudar-Milovanović, E., Vučić, V., Arsić, A., Nedić, O., Šunderić, M., Gligorijević, N., Milačić, D.,& Isenović, E. R.. (2020). Effect of Hyperbaric Oxygen Therapy on Fatty Acid Composition and Insulin-like Growth Factor Binding Protein 1 in Adult Type 1 Diabetes Mellitus Patients: A Pilot Study. in Canadian Journal of Diabetes, 44(1), 22-29.
https://doi.org/10.1016/j.jcjd.2019.04.018

Resanović I, Gluvić Z, Zarić B, Sudar-Milovanović E, Vučić V, Arsić A, Nedić O, Šunderić M, Gligorijević N, Milačić D, Isenović ER. Effect of Hyperbaric Oxygen Therapy on Fatty Acid Composition and Insulin-like Growth Factor Binding Protein 1 in Adult Type 1 Diabetes Mellitus Patients: A Pilot Study. in Canadian Journal of Diabetes. 2020;44(1):22-29.
doi:10.1016/j.jcjd.2019.04.018 .

Resanović, Ivana, Gluvić, Zoran, Zarić, Božidarka, Sudar-Milovanović, Emina, Vučić, Vesna, Arsić, Aleksandra, Nedić, Olgica, Šunderić, Miloš, Gligorijević, Nikola, Milačić, Davorka, Isenović, Esma R., "Effect of Hyperbaric Oxygen Therapy on Fatty Acid Composition and Insulin-like Growth Factor Binding Protein 1 in Adult Type 1 Diabetes Mellitus Patients: A Pilot Study" in Canadian Journal of Diabetes, 44, no. 1 (2020):22-29,
https://doi.org/10.1016/j.jcjd.2019.04.018 . .

TY  - JOUR
AU  - Dugalić, Predrag
AU  - Đuranović, Srđan
AU  - Pavlović-Marković, Aleksandra
AU  - Dugalić, Vladimir
AU  - Tomašević, Ratko
AU  - Gluvić, Zoran
AU  - Obradović, Milan M.
AU  - Bajić, Vladan P.
AU  - Isenović, Esma R.
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9104
AB  - Gastroesophageal Reflux Disease (GERD) is characterized by acid and bile reflux in the dis-tal oesophagus, and this may cause the development of reflux esophagitis and Barrett’s oesophagus (BE). The natural histological course of untreated BE is non-dysplastic or benign BE (ND), then low-grade (LGD) and High-Grade Dysplastic (HGD) BE, with the expected increase in malignancy transfer to oesophagal adenocarcinoma (EAC). The gold standard for BE diagnostics involves high-resolution white-light endoscopy, followed by uniform endoscopy findings description (Prague classification) with biopsy performance according to Seattle protocol. The medical treatment of GERD and BE includes the use of proton pump inhibitors (PPIs) regarding symptoms control. It is noteworthy that long-term use of PPIs increases gastrin level, which can contribute to transfer from BE to EAC, as a result of its effects on the proliferation of BE epithelium. Endoscopy treatment includes a wide range of re-section and ablative techniques, such as radio-frequency ablation (RFA), often concomitantly used in everyday endoscopy practice (multimodal therapy). RFA promotes mucosal necrosis of treated oesophagal region via high-frequency energy. Laparoscopic surgery, partial or total fundoplication, is reserved for PPIs and endoscopy indolent patients or in those with progressive disease. This review aims to explain distinct effects of PPIs and RFA modalities, illuminate certain aspects of molecular mechanisms involved, as well as the effects of their concomitant use regarding the treatment of BE and prevention of its transfer to EAC.
T2  - Mini-Reviews in Medicinal Chemistry
T1  - Proton Pump Inhibitors and Radiofrequency Ablation for Treatment of Barrett's Esophagus
VL  - 20
IS  - 11
SP  - 975
EP  - 987
DO  - 10.2174/1389557519666191015203636
ER  - 

@article{
author = "Dugalić, Predrag and Đuranović, Srđan and Pavlović-Marković, Aleksandra and Dugalić, Vladimir and Tomašević, Ratko and Gluvić, Zoran and Obradović, Milan M. and Bajić, Vladan P. and Isenović, Esma R.",
year = "2020",
abstract = "Gastroesophageal Reflux Disease (GERD) is characterized by acid and bile reflux in the dis-tal oesophagus, and this may cause the development of reflux esophagitis and Barrett’s oesophagus (BE). The natural histological course of untreated BE is non-dysplastic or benign BE (ND), then low-grade (LGD) and High-Grade Dysplastic (HGD) BE, with the expected increase in malignancy transfer to oesophagal adenocarcinoma (EAC). The gold standard for BE diagnostics involves high-resolution white-light endoscopy, followed by uniform endoscopy findings description (Prague classification) with biopsy performance according to Seattle protocol. The medical treatment of GERD and BE includes the use of proton pump inhibitors (PPIs) regarding symptoms control. It is noteworthy that long-term use of PPIs increases gastrin level, which can contribute to transfer from BE to EAC, as a result of its effects on the proliferation of BE epithelium. Endoscopy treatment includes a wide range of re-section and ablative techniques, such as radio-frequency ablation (RFA), often concomitantly used in everyday endoscopy practice (multimodal therapy). RFA promotes mucosal necrosis of treated oesophagal region via high-frequency energy. Laparoscopic surgery, partial or total fundoplication, is reserved for PPIs and endoscopy indolent patients or in those with progressive disease. This review aims to explain distinct effects of PPIs and RFA modalities, illuminate certain aspects of molecular mechanisms involved, as well as the effects of their concomitant use regarding the treatment of BE and prevention of its transfer to EAC.",
journal = "Mini-Reviews in Medicinal Chemistry",
title = "Proton Pump Inhibitors and Radiofrequency Ablation for Treatment of Barrett's Esophagus",
volume = "20",
number = "11",
pages = "975-987",
doi = "10.2174/1389557519666191015203636"
}

Dugalić, P., Đuranović, S., Pavlović-Marković, A., Dugalić, V., Tomašević, R., Gluvić, Z., Obradović, M. M., Bajić, V. P.,& Isenović, E. R.. (2020). Proton Pump Inhibitors and Radiofrequency Ablation for Treatment of Barrett's Esophagus. in Mini-Reviews in Medicinal Chemistry, 20(11), 975-987.
https://doi.org/10.2174/1389557519666191015203636

Dugalić P, Đuranović S, Pavlović-Marković A, Dugalić V, Tomašević R, Gluvić Z, Obradović MM, Bajić VP, Isenović ER. Proton Pump Inhibitors and Radiofrequency Ablation for Treatment of Barrett's Esophagus. in Mini-Reviews in Medicinal Chemistry. 2020;20(11):975-987.
doi:10.2174/1389557519666191015203636 .

Dugalić, Predrag, Đuranović, Srđan, Pavlović-Marković, Aleksandra, Dugalić, Vladimir, Tomašević, Ratko, Gluvić, Zoran, Obradović, Milan M., Bajić, Vladan P., Isenović, Esma R., "Proton Pump Inhibitors and Radiofrequency Ablation for Treatment of Barrett's Esophagus" in Mini-Reviews in Medicinal Chemistry, 20, no. 11 (2020):975-987,
https://doi.org/10.2174/1389557519666191015203636 . .

TY  - JOUR
AU  - Zarić, Božidarka
AU  - Radovanović, Jelena N.
AU  - Gluvić, Zoran
AU  - Stewart, Alan J.
AU  - Essack, Magbubah
AU  - Motwalli, Olaa
AU  - Gojobori, Takashi
AU  - Isenović, Esma R.
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9681
AB  - Cardiovascular disease is the leading global health concern and responsible for more deaths worldwide than any other type of disorder. Atherosclerosis is a chronic inflammatory disease in the arterial wall, which underpins several types of cardiovascular disease. It has emerged that a strong relationship exists between alterations in amino acid (AA) metabolism and the development of atherosclerosis. Recent studies have reported positive correlations between levels of branched-chain amino acids (BCAAs) such as leucine, valine, and isoleucine in plasma and the occurrence of metabolic disturbances. Elevated serum levels of BCAAs indicate a high cardiometabolic risk. Thus, BCAAs may also impact atherosclerosis prevention and offer a novel therapeutic strategy for specific individuals at risk of coronary events. The metabolism of AAs, such as L-arginine, homoarginine, and L-tryptophan, is recognized as a critical regulator of vascular homeostasis. Dietary intake of homoarginine, taurine, and glycine can improve atherosclerosis by endothelium remodeling. Available data also suggest that the regulation of AA metabolism by indoleamine 2,3-dioxygenase (IDO) and arginases 1 and 2 are mediated through various immunological signals and that immunosuppressive AA metabolizing enzymes are promising therapeutic targets against atherosclerosis. Further clinical studies and basic studies that make use of animal models are required. Here we review recent data examining links between AA metabolism and the development of atherosclerosis.
T2  - Frontiers in Immunology
T1  - Atherosclerosis Linked to Aberrant Amino Acid Metabolism and Immunosuppressive Amino Acid Catabolizing Enzymes
VL  - 11
SP  - 2341
DO  - 10.3389/fimmu.2020.551758
ER  - 

@article{
author = "Zarić, Božidarka and Radovanović, Jelena N. and Gluvić, Zoran and Stewart, Alan J. and Essack, Magbubah and Motwalli, Olaa and Gojobori, Takashi and Isenović, Esma R.",
year = "2020",
abstract = "Cardiovascular disease is the leading global health concern and responsible for more deaths worldwide than any other type of disorder. Atherosclerosis is a chronic inflammatory disease in the arterial wall, which underpins several types of cardiovascular disease. It has emerged that a strong relationship exists between alterations in amino acid (AA) metabolism and the development of atherosclerosis. Recent studies have reported positive correlations between levels of branched-chain amino acids (BCAAs) such as leucine, valine, and isoleucine in plasma and the occurrence of metabolic disturbances. Elevated serum levels of BCAAs indicate a high cardiometabolic risk. Thus, BCAAs may also impact atherosclerosis prevention and offer a novel therapeutic strategy for specific individuals at risk of coronary events. The metabolism of AAs, such as L-arginine, homoarginine, and L-tryptophan, is recognized as a critical regulator of vascular homeostasis. Dietary intake of homoarginine, taurine, and glycine can improve atherosclerosis by endothelium remodeling. Available data also suggest that the regulation of AA metabolism by indoleamine 2,3-dioxygenase (IDO) and arginases 1 and 2 are mediated through various immunological signals and that immunosuppressive AA metabolizing enzymes are promising therapeutic targets against atherosclerosis. Further clinical studies and basic studies that make use of animal models are required. Here we review recent data examining links between AA metabolism and the development of atherosclerosis.",
journal = "Frontiers in Immunology",
title = "Atherosclerosis Linked to Aberrant Amino Acid Metabolism and Immunosuppressive Amino Acid Catabolizing Enzymes",
volume = "11",
pages = "2341",
doi = "10.3389/fimmu.2020.551758"
}

Zarić, B., Radovanović, J. N., Gluvić, Z., Stewart, A. J., Essack, M., Motwalli, O., Gojobori, T.,& Isenović, E. R.. (2020). Atherosclerosis Linked to Aberrant Amino Acid Metabolism and Immunosuppressive Amino Acid Catabolizing Enzymes. in Frontiers in Immunology, 11, 2341.
https://doi.org/10.3389/fimmu.2020.551758

Zarić B, Radovanović JN, Gluvić Z, Stewart AJ, Essack M, Motwalli O, Gojobori T, Isenović ER. Atherosclerosis Linked to Aberrant Amino Acid Metabolism and Immunosuppressive Amino Acid Catabolizing Enzymes. in Frontiers in Immunology. 2020;11:2341.
doi:10.3389/fimmu.2020.551758 .

Zarić, Božidarka, Radovanović, Jelena N., Gluvić, Zoran, Stewart, Alan J., Essack, Magbubah, Motwalli, Olaa, Gojobori, Takashi, Isenović, Esma R., "Atherosclerosis Linked to Aberrant Amino Acid Metabolism and Immunosuppressive Amino Acid Catabolizing Enzymes" in Frontiers in Immunology, 11 (2020):2341,
https://doi.org/10.3389/fimmu.2020.551758 . .

TY  - JOUR
AU  - Gluvić, Zoran
AU  - Lacković, Milena
AU  - Samardžić, Vladimir
AU  - Mitrović, Bojan
AU  - Mladenović, Violeta
AU  - Obradović, Milan
AU  - Jevremović, Danimir
AU  - Isenović, Esma R.
PY  - 2019
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12027
AB  - Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disorder with mutations in genes involved in cortisol and aldosterone production. Based on overall 21-OHase activity, CAH is divided into classic (C-CAH) and non-classic (NC-CAH). Females who suffered from NC-CAH have had increased infertility rates and higher miscarriage susceptibility. The treatment of CAH in pregnancy is still debatable. We present 22-years-old pregnant female (seventh week of gestation), who is currently under dexamethasone (DEX) since almost seven years for NC-CAH. At presentation, she is normotensive, non-obese, with no signs of hirsutism and Cushing syndrome. Seven days after the first visit, an endocrinologist makes informative talk with the patient and her mother about NC-CAH, pregnancy, and drugsassociated risks. Current Clinical Practice Guideline for CAH treatment suggests the use of protocols approved by Institutional Review Boards at Centers experienced in CAH treatment. In women with CAH who are planning a pregnancy, a close relationship between endocrinologist, reproductive gynaecologist and molecular biologist is of great interest. Prenatal management with DEX is advised in particular circumstances. In remaining, the switch from DEX to other glucocorticoids that do not penetrate placenta is advised
T2  - Clinical Medical Reviews and Case Reports
T1  - Management of Non-Classic Congenital Adrenal Hyperplasia in Pregnant Woman - Non-Referral Center Experience- Case Report
VL  - 6
IS  - 2
DO  - 10.23937/2378-3656/1410257
ER  - 

@article{
author = "Gluvić, Zoran and Lacković, Milena and Samardžić, Vladimir and Mitrović, Bojan and Mladenović, Violeta and Obradović, Milan and Jevremović, Danimir and Isenović, Esma R.",
year = "2019",
abstract = "Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disorder with mutations in genes involved in cortisol and aldosterone production. Based on overall 21-OHase activity, CAH is divided into classic (C-CAH) and non-classic (NC-CAH). Females who suffered from NC-CAH have had increased infertility rates and higher miscarriage susceptibility. The treatment of CAH in pregnancy is still debatable. We present 22-years-old pregnant female (seventh week of gestation), who is currently under dexamethasone (DEX) since almost seven years for NC-CAH. At presentation, she is normotensive, non-obese, with no signs of hirsutism and Cushing syndrome. Seven days after the first visit, an endocrinologist makes informative talk with the patient and her mother about NC-CAH, pregnancy, and drugsassociated risks. Current Clinical Practice Guideline for CAH treatment suggests the use of protocols approved by Institutional Review Boards at Centers experienced in CAH treatment. In women with CAH who are planning a pregnancy, a close relationship between endocrinologist, reproductive gynaecologist and molecular biologist is of great interest. Prenatal management with DEX is advised in particular circumstances. In remaining, the switch from DEX to other glucocorticoids that do not penetrate placenta is advised",
journal = "Clinical Medical Reviews and Case Reports",
title = "Management of Non-Classic Congenital Adrenal Hyperplasia in Pregnant Woman - Non-Referral Center Experience- Case Report",
volume = "6",
number = "2",
doi = "10.23937/2378-3656/1410257"
}

Gluvić, Z., Lacković, M., Samardžić, V., Mitrović, B., Mladenović, V., Obradović, M., Jevremović, D.,& Isenović, E. R.. (2019). Management of Non-Classic Congenital Adrenal Hyperplasia in Pregnant Woman - Non-Referral Center Experience- Case Report. in Clinical Medical Reviews and Case Reports, 6(2).
https://doi.org/10.23937/2378-3656/1410257

Gluvić Z, Lacković M, Samardžić V, Mitrović B, Mladenović V, Obradović M, Jevremović D, Isenović ER. Management of Non-Classic Congenital Adrenal Hyperplasia in Pregnant Woman - Non-Referral Center Experience- Case Report. in Clinical Medical Reviews and Case Reports. 2019;6(2).
doi:10.23937/2378-3656/1410257 .

Gluvić, Zoran, Lacković, Milena, Samardžić, Vladimir, Mitrović, Bojan, Mladenović, Violeta, Obradović, Milan, Jevremović, Danimir, Isenović, Esma R., "Management of Non-Classic Congenital Adrenal Hyperplasia in Pregnant Woman - Non-Referral Center Experience- Case Report" in Clinical Medical Reviews and Case Reports, 6, no. 2 (2019),
https://doi.org/10.23937/2378-3656/1410257 . .

TY  - JOUR
AU  - Resanović, Ivana
AU  - Gluvić, Zoran
AU  - Zarić, Božidarka
AU  - Sudar-Milovanović, Emina
AU  - Jovanović, Aleksandra
AU  - Milačić, Davorka
AU  - Isaković, Radmilo
AU  - Isenović, Esma R.
PY  - 2019
UR  - https://www.hindawi.com/journals/ije/2019/2328505/
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8209
AB  - This study aimed at examining the early effects of hyperbaric oxygen therapy (HBOT) on inducible nitric oxide synthase (iNOS) activity/expression in lymphocytes of type 1 diabetes mellitus (T1DM) patients. A group of 19 patients (mean age: 63 ± 2.1) with T1DM and with the peripheral arterial disease were included in this study. Patients were exposed to 10 sessions of HBOT in the duration of 1 h to 100% oxygen inhalation at 2.4 ATA. Blood samples were collected for the plasma C-reactive protein (CRP), plasma free fatty acid (FFA), serum nitrite/nitrate, and serum arginase activity measurements. Expression of iNOS and phosphorylation of p65 subunit of nuclear factor- κ B (NF κ B-p65), extracellular-regulated kinases 1/2 (ERK1/2), and protein kinase B (Akt) were examined in lymphocyte lysates by Western blot. After exposure to HBOT, plasma CRP and FFA were significantly decreased ( p < 0.001 ). Protein expression of iNOS and serum nitrite/nitrate levels were decreased ( p < 0.01 ), while serum arginase activity was increased ( p < 0.05 ) versus before exposure to HBOT. Increased phosphorylation of NF κ B-p65 at Ser 536 ( p < 0.05 ) and decreased level of NF κ B-p65 protein ( p < 0.001 ) in lymphocytes of T1DM patients were observed after HBOT. Decreased phosphorylation of ERK1/2 ( p < 0.05 ) and Akt ( p < 0.05 ) was detected after HBOT. Our results indicate that exposure to HBO decreased iNOS activity/expression via decreasing phosphorylation of ERK1/2 and Akt followed by decreased activity of NF κ B.
T2  - International Journal of Endocrinology
T1  - Early Effects of Hyperbaric Oxygen on Inducible Nitric Oxide Synthase Activity/Expression in Lymphocytes of Type 1 Diabetes Patients: A Prospective Pilot Study
VL  - 2019
SP  - 1
EP  - 12
DO  - 10.1155/2019/2328505
ER  - 

@article{
author = "Resanović, Ivana and Gluvić, Zoran and Zarić, Božidarka and Sudar-Milovanović, Emina and Jovanović, Aleksandra and Milačić, Davorka and Isaković, Radmilo and Isenović, Esma R.",
year = "2019",
abstract = "This study aimed at examining the early effects of hyperbaric oxygen therapy (HBOT) on inducible nitric oxide synthase (iNOS) activity/expression in lymphocytes of type 1 diabetes mellitus (T1DM) patients. A group of 19 patients (mean age: 63 ± 2.1) with T1DM and with the peripheral arterial disease were included in this study. Patients were exposed to 10 sessions of HBOT in the duration of 1 h to 100% oxygen inhalation at 2.4 ATA. Blood samples were collected for the plasma C-reactive protein (CRP), plasma free fatty acid (FFA), serum nitrite/nitrate, and serum arginase activity measurements. Expression of iNOS and phosphorylation of p65 subunit of nuclear factor- κ B (NF κ B-p65), extracellular-regulated kinases 1/2 (ERK1/2), and protein kinase B (Akt) were examined in lymphocyte lysates by Western blot. After exposure to HBOT, plasma CRP and FFA were significantly decreased ( p < 0.001 ). Protein expression of iNOS and serum nitrite/nitrate levels were decreased ( p < 0.01 ), while serum arginase activity was increased ( p < 0.05 ) versus before exposure to HBOT. Increased phosphorylation of NF κ B-p65 at Ser 536 ( p < 0.05 ) and decreased level of NF κ B-p65 protein ( p < 0.001 ) in lymphocytes of T1DM patients were observed after HBOT. Decreased phosphorylation of ERK1/2 ( p < 0.05 ) and Akt ( p < 0.05 ) was detected after HBOT. Our results indicate that exposure to HBO decreased iNOS activity/expression via decreasing phosphorylation of ERK1/2 and Akt followed by decreased activity of NF κ B.",
journal = "International Journal of Endocrinology",
title = "Early Effects of Hyperbaric Oxygen on Inducible Nitric Oxide Synthase Activity/Expression in Lymphocytes of Type 1 Diabetes Patients: A Prospective Pilot Study",
volume = "2019",
pages = "1-12",
doi = "10.1155/2019/2328505"
}

Resanović, I., Gluvić, Z., Zarić, B., Sudar-Milovanović, E., Jovanović, A., Milačić, D., Isaković, R.,& Isenović, E. R.. (2019). Early Effects of Hyperbaric Oxygen on Inducible Nitric Oxide Synthase Activity/Expression in Lymphocytes of Type 1 Diabetes Patients: A Prospective Pilot Study. in International Journal of Endocrinology, 2019, 1-12.
https://doi.org/10.1155/2019/2328505

Resanović I, Gluvić Z, Zarić B, Sudar-Milovanović E, Jovanović A, Milačić D, Isaković R, Isenović ER. Early Effects of Hyperbaric Oxygen on Inducible Nitric Oxide Synthase Activity/Expression in Lymphocytes of Type 1 Diabetes Patients: A Prospective Pilot Study. in International Journal of Endocrinology. 2019;2019:1-12.
doi:10.1155/2019/2328505 .

Resanović, Ivana, Gluvić, Zoran, Zarić, Božidarka, Sudar-Milovanović, Emina, Jovanović, Aleksandra, Milačić, Davorka, Isaković, Radmilo, Isenović, Esma R., "Early Effects of Hyperbaric Oxygen on Inducible Nitric Oxide Synthase Activity/Expression in Lymphocytes of Type 1 Diabetes Patients: A Prospective Pilot Study" in International Journal of Endocrinology, 2019 (2019):1-12,
https://doi.org/10.1155/2019/2328505 . .

TY  - JOUR
AU  - Gluvić, Zoran
AU  - Sudar-Milovanović, Emina
AU  - Samardžić, Vladimir S.
AU  - Obradović, Milan M.
AU  - Jevremović, Danimir P.
AU  - Radenković, Saša P.
AU  - Isenović, Esma R.
PY  - 2019
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8369
AB  - Primary hypothyroidism can affect lipid metabolism, cardiovascular (CV) function, and overall patients’ quality of life (QoL). Decrease in serum nitric oxide (NO) levels could promote the atherosclerosis acceleration in hypothyroid patients. Our hypothesis is that serum NO level is altered in hypothyroidism; more specifically, we hypothesize that the early vascular changes that can be observed in hypothyroidism could be due to these alterations and that serum NO levels are associated with lipid levels in female patients diagnosed with subclinical hypothyroidism (SCH) or clinical hypothyroidism (CH). Furthermore, since serum NO level is an early marker of atherosclerosis and related CV disorders, which are commonly present and follow hypothyreosis and greatly contribute to overall QoL, we further hypothesized that NO level would correlate with Thyroid Symptom Questionnaire (TSQ) and General Health Questionnaire 12 (GHQ12) scores in hypothyroid patients. A collaterally of our hypothesis was that levothyroxine (LT4) treatment would affect serum NO levels as well as TSQ and GHQ12 scores. Therefore, we have analyzed lipid profile, the level of NO and QoL scores in female patients diagnosed with SCH and CH in order to determine the correlation between NO and generic and thyroid disease symptoms in treatment naïve SCH and CH patients and after LT4 treatment and laboratory euthyroidism achievement. As a consequence of our hypothesis is that measurement of serum NO level in SCH and CH patients may be an innovative way to improve LT4 treatment efficacy. This assumption could have a practical significance for future investigations regarding the management of hypothyroidism treatment protocols in current guidelines. © 2019 Elsevier Ltd
T2  - Medical Hypotheses
T1  - Serum nitric oxide levels correlate with quality of life questionnaires scores of hypothyroid females
VL  - 131
SP  - 109299
DO  - 10.1016/j.mehy.2019.109299
ER  - 

@article{
author = "Gluvić, Zoran and Sudar-Milovanović, Emina and Samardžić, Vladimir S. and Obradović, Milan M. and Jevremović, Danimir P. and Radenković, Saša P. and Isenović, Esma R.",
year = "2019",
abstract = "Primary hypothyroidism can affect lipid metabolism, cardiovascular (CV) function, and overall patients’ quality of life (QoL). Decrease in serum nitric oxide (NO) levels could promote the atherosclerosis acceleration in hypothyroid patients. Our hypothesis is that serum NO level is altered in hypothyroidism; more specifically, we hypothesize that the early vascular changes that can be observed in hypothyroidism could be due to these alterations and that serum NO levels are associated with lipid levels in female patients diagnosed with subclinical hypothyroidism (SCH) or clinical hypothyroidism (CH). Furthermore, since serum NO level is an early marker of atherosclerosis and related CV disorders, which are commonly present and follow hypothyreosis and greatly contribute to overall QoL, we further hypothesized that NO level would correlate with Thyroid Symptom Questionnaire (TSQ) and General Health Questionnaire 12 (GHQ12) scores in hypothyroid patients. A collaterally of our hypothesis was that levothyroxine (LT4) treatment would affect serum NO levels as well as TSQ and GHQ12 scores. Therefore, we have analyzed lipid profile, the level of NO and QoL scores in female patients diagnosed with SCH and CH in order to determine the correlation between NO and generic and thyroid disease symptoms in treatment naïve SCH and CH patients and after LT4 treatment and laboratory euthyroidism achievement. As a consequence of our hypothesis is that measurement of serum NO level in SCH and CH patients may be an innovative way to improve LT4 treatment efficacy. This assumption could have a practical significance for future investigations regarding the management of hypothyroidism treatment protocols in current guidelines. © 2019 Elsevier Ltd",
journal = "Medical Hypotheses",
title = "Serum nitric oxide levels correlate with quality of life questionnaires scores of hypothyroid females",
volume = "131",
pages = "109299",
doi = "10.1016/j.mehy.2019.109299"
}

Gluvić, Z., Sudar-Milovanović, E., Samardžić, V. S., Obradović, M. M., Jevremović, D. P., Radenković, S. P.,& Isenović, E. R.. (2019). Serum nitric oxide levels correlate with quality of life questionnaires scores of hypothyroid females. in Medical Hypotheses, 131, 109299.
https://doi.org/10.1016/j.mehy.2019.109299

Gluvić Z, Sudar-Milovanović E, Samardžić VS, Obradović MM, Jevremović DP, Radenković SP, Isenović ER. Serum nitric oxide levels correlate with quality of life questionnaires scores of hypothyroid females. in Medical Hypotheses. 2019;131:109299.
doi:10.1016/j.mehy.2019.109299 .

Gluvić, Zoran, Sudar-Milovanović, Emina, Samardžić, Vladimir S., Obradović, Milan M., Jevremović, Danimir P., Radenković, Saša P., Isenović, Esma R., "Serum nitric oxide levels correlate with quality of life questionnaires scores of hypothyroid females" in Medical Hypotheses, 131 (2019):109299,
https://doi.org/10.1016/j.mehy.2019.109299 . .

TY  - JOUR
AU  - Gluvić, Zoran
AU  - Obradović, Milan M.
AU  - Lačković, Milena
AU  - Samardžić, Vladimir S.
AU  - Tica Jevtic, Jelena
AU  - Essack, Magbubah
AU  - Bajić, Vladimir B.
AU  - Isenović, Esma R.
PY  - 2019
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8484
AB  - What is known and objective: The HbA1C marker used in assessing diabetes control quality is not sufficient in diabetes patients with thalassaemia. Case description: A male diabetic patient with thalassaemia was hospitalized due to distal neuropathic pain, right toe trophic ulcer, unacceptable five-point glycaemic profile and recommended HbA1C value. After simultaneously initiated insulin therapy and management of ulcer by hyperbaric oxygen, the patient showed improved glycaemic control and ulcer healing, which led to the patient's discharge. What is new and conclusion: In thalassaemia and haemoglobinopathies, due to discrepancies in the five-point glycaemic profile and HbA1C values, it is necessary to measure HbA1C with a different method or to determine HbA1C and fructosamine simultaneously. © 2019 The Authors. Journal of Clinical Pharmacy and Therapeutics Published by John Wiley & Sons Ltd.
T2  - Journal of Clinical Pharmacy and Therapeutics
T1  - HbA1C as a marker of retrograde glycaemic control in diabetes patient with co-existed beta-thalassaemia: A case report and a literature review
VL  - 45
IS  - 2
SP  - 379
EP  - 383
DO  - 10.1111/jcpt.13073
ER  - 

@article{
author = "Gluvić, Zoran and Obradović, Milan M. and Lačković, Milena and Samardžić, Vladimir S. and Tica Jevtic, Jelena and Essack, Magbubah and Bajić, Vladimir B. and Isenović, Esma R.",
year = "2019",
abstract = "What is known and objective: The HbA1C marker used in assessing diabetes control quality is not sufficient in diabetes patients with thalassaemia. Case description: A male diabetic patient with thalassaemia was hospitalized due to distal neuropathic pain, right toe trophic ulcer, unacceptable five-point glycaemic profile and recommended HbA1C value. After simultaneously initiated insulin therapy and management of ulcer by hyperbaric oxygen, the patient showed improved glycaemic control and ulcer healing, which led to the patient's discharge. What is new and conclusion: In thalassaemia and haemoglobinopathies, due to discrepancies in the five-point glycaemic profile and HbA1C values, it is necessary to measure HbA1C with a different method or to determine HbA1C and fructosamine simultaneously. © 2019 The Authors. Journal of Clinical Pharmacy and Therapeutics Published by John Wiley & Sons Ltd.",
journal = "Journal of Clinical Pharmacy and Therapeutics",
title = "HbA1C as a marker of retrograde glycaemic control in diabetes patient with co-existed beta-thalassaemia: A case report and a literature review",
volume = "45",
number = "2",
pages = "379-383",
doi = "10.1111/jcpt.13073"
}

Gluvić, Z., Obradović, M. M., Lačković, M., Samardžić, V. S., Tica Jevtic, J., Essack, M., Bajić, V. B.,& Isenović, E. R.. (2019). HbA1C as a marker of retrograde glycaemic control in diabetes patient with co-existed beta-thalassaemia: A case report and a literature review. in Journal of Clinical Pharmacy and Therapeutics, 45(2), 379-383.
https://doi.org/10.1111/jcpt.13073

Gluvić Z, Obradović MM, Lačković M, Samardžić VS, Tica Jevtic J, Essack M, Bajić VB, Isenović ER. HbA1C as a marker of retrograde glycaemic control in diabetes patient with co-existed beta-thalassaemia: A case report and a literature review. in Journal of Clinical Pharmacy and Therapeutics. 2019;45(2):379-383.
doi:10.1111/jcpt.13073 .

Gluvić, Zoran, Obradović, Milan M., Lačković, Milena, Samardžić, Vladimir S., Tica Jevtic, Jelena, Essack, Magbubah, Bajić, Vladimir B., Isenović, Esma R., "HbA1C as a marker of retrograde glycaemic control in diabetes patient with co-existed beta-thalassaemia: A case report and a literature review" in Journal of Clinical Pharmacy and Therapeutics, 45, no. 2 (2019):379-383,
https://doi.org/10.1111/jcpt.13073 . .

TY  - JOUR
AU  - Gluvić, Zoran
AU  - Mitrović, Bojan
AU  - Lačković, Milena
AU  - Samardžić, Vladimir
AU  - Jakšić, Dunja
AU  - Pavlović, Aleksandar
AU  - Tomašević, Ratko
AU  - Obradović, Milan M.
AU  - Isenović, Esma R.
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10153
AB  - Staphylococcal toxic shock syndrome (STSS) is typically detected in newborns and children but can be seen in adults occasionally. In such a case, it points out usually on some immune system dysfunction. We present a case of a critically-ill adult male with STSS and symptoms and signs of serious systemic infection (hemodynamic instability, acute renal failure, mental confusion). After the completion of applied treatment (antistaphylococcal antimicrobials, hemodialysis, vasopressor, supportive, and symptomatic therapy), complete restoration of presented patients' derangements was achieved. Timely diagnosis and appropriate treatment is the mainstay in the management of STSS in adults.
AB  - Stafilokokni toksični šok sindrom (STŠS) se obično javlja kod novorođenčadi i dece, ali se povremeno može javiti i kod odraslih. U tom slučaju, obično ukazuje na disfunkciju imunog sistema. Prikazan je slučaj kritično-obolelog odraslog muškarca sa STŠS i simptomima i znacima životno-ugrožavajuće sistemske infekcije (hemodinamska nestabilnost, akutna insuficijencija bubrega, konfuzija). Nakon završenog lečenja (anti-stafilokoni antibiotici, hemodijaliza, vazopresori, suportivna i simptomatska terapija), postignuta je potpuna remisija kod obolelog. Pravovremena dijagnostika i adekvatan tretman je glavno uporište u lečenju STŠS kod odraslih.
T2  - Materia medica
T1  - An old fox is trapped: The staphylococcal toxic shock syndrome in male adult: Case report
T1  - Uhvaćen je stari lisac - stafilokokni toksični šok sindrom kod odraslog muškarca - prikaz slučaja
VL  - 34
IS  - 3
SP  - 1608
EP  - 1612
DO  - 10.5937/MatMed1801608G
ER  - 

@article{
author = "Gluvić, Zoran and Mitrović, Bojan and Lačković, Milena and Samardžić, Vladimir and Jakšić, Dunja and Pavlović, Aleksandar and Tomašević, Ratko and Obradović, Milan M. and Isenović, Esma R.",
year = "2018",
abstract = "Staphylococcal toxic shock syndrome (STSS) is typically detected in newborns and children but can be seen in adults occasionally. In such a case, it points out usually on some immune system dysfunction. We present a case of a critically-ill adult male with STSS and symptoms and signs of serious systemic infection (hemodynamic instability, acute renal failure, mental confusion). After the completion of applied treatment (antistaphylococcal antimicrobials, hemodialysis, vasopressor, supportive, and symptomatic therapy), complete restoration of presented patients' derangements was achieved. Timely diagnosis and appropriate treatment is the mainstay in the management of STSS in adults., Stafilokokni toksični šok sindrom (STŠS) se obično javlja kod novorođenčadi i dece, ali se povremeno može javiti i kod odraslih. U tom slučaju, obično ukazuje na disfunkciju imunog sistema. Prikazan je slučaj kritično-obolelog odraslog muškarca sa STŠS i simptomima i znacima životno-ugrožavajuće sistemske infekcije (hemodinamska nestabilnost, akutna insuficijencija bubrega, konfuzija). Nakon završenog lečenja (anti-stafilokoni antibiotici, hemodijaliza, vazopresori, suportivna i simptomatska terapija), postignuta je potpuna remisija kod obolelog. Pravovremena dijagnostika i adekvatan tretman je glavno uporište u lečenju STŠS kod odraslih.",
journal = "Materia medica",
title = "An old fox is trapped: The staphylococcal toxic shock syndrome in male adult: Case report, Uhvaćen je stari lisac - stafilokokni toksični šok sindrom kod odraslog muškarca - prikaz slučaja",
volume = "34",
number = "3",
pages = "1608-1612",
doi = "10.5937/MatMed1801608G"
}

Gluvić, Z., Mitrović, B., Lačković, M., Samardžić, V., Jakšić, D., Pavlović, A., Tomašević, R., Obradović, M. M.,& Isenović, E. R.. (2018). An old fox is trapped: The staphylococcal toxic shock syndrome in male adult: Case report. in Materia medica, 34(3), 1608-1612.
https://doi.org/10.5937/MatMed1801608G

Gluvić Z, Mitrović B, Lačković M, Samardžić V, Jakšić D, Pavlović A, Tomašević R, Obradović MM, Isenović ER. An old fox is trapped: The staphylococcal toxic shock syndrome in male adult: Case report. in Materia medica. 2018;34(3):1608-1612.
doi:10.5937/MatMed1801608G .

Gluvić, Zoran, Mitrović, Bojan, Lačković, Milena, Samardžić, Vladimir, Jakšić, Dunja, Pavlović, Aleksandar, Tomašević, Ratko, Obradović, Milan M., Isenović, Esma R., "An old fox is trapped: The staphylococcal toxic shock syndrome in male adult: Case report" in Materia medica, 34, no. 3 (2018):1608-1612,
https://doi.org/10.5937/MatMed1801608G . .

TY  - JOUR
AU  - Stanimirović, Julijana
AU  - Obradović, Milan M.
AU  - Gluvić, Zoran
AU  - Isenović, Esma R.
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10154
AB  - Jetra ima važnu ulogu u održavanju metaboličke homeostaze i predstavlja mesto kompleksne regulacije metabolizma supstrata (ugljenih hidrata, lipida i proteina) od strane insulina i drugih hormona. Proteklih decenija ističe se značaj metaboličkih funkcija jetre u brojnim patološkim stanjima. Mehanizmi kojima gojaznost dovodi do poremećaja metaboličkih procesa u jetri su danas predmet mnogobrojnih istraživanja. Metaboličke i hormonske promene koje su posledica prevashodno visceralne gojaznosti, dovode vremenom do nagomilavanja lipida u jetri. Povećana učestalost gojaznosti i razvoj metaboličkog sindroma doprinose pojavi patofizioloških promena u jetri i razvoju nealkoholne bolesti masne jetre (NAFLD), jednoj od najčešćih bolesti jetre u zapadnoevropskim zemljama. U ovom preglednom članku razmotrili smo najnovije literaturne podatke koji se odnose na ulogu jetre u metabolizmu glukoze i lipida u stanju gojaznosti.
AB  - The liver plays a vital role in metabolic homeostasis and represents a major site for complex regulation of substrates (carbohydrates, lipids, and proteins) by insulin and other hormones. The significance of liver metabolic functions in many pathophysiological conditions is highlighted over the past decades. Mechanisms of obesity-induced metabolic disturbance in the liver are the topic of numerous research studies. Metabolic and hormonal changes which are caused primarily by visceral obesity lead to hepatic lipid accumulation. Increased prevalence of obesity and the development of metabolic syndrome contribute to pathophysiological changes in the liver and development of non-alcoholic fatty liver disease (NAFLD), one of the most common diseases in Western societies. In this review, we discussed most recent literature data related to the role of the liver in glucose and lipid metabolism in obesity.
T2  - Medicinska istraživanja
T1  - Uloga jetre u metabolizmu glukoze i lipida u stanju gojaznosti
T1  - The role of the liver in glucose and lipid metabolism in obesity
VL  - 52
IS  - 3
SP  - 1
EP  - 6
DO  - 10.5937/MedIst1803001S
ER  - 

@article{
author = "Stanimirović, Julijana and Obradović, Milan M. and Gluvić, Zoran and Isenović, Esma R.",
year = "2018",
abstract = "Jetra ima važnu ulogu u održavanju metaboličke homeostaze i predstavlja mesto kompleksne regulacije metabolizma supstrata (ugljenih hidrata, lipida i proteina) od strane insulina i drugih hormona. Proteklih decenija ističe se značaj metaboličkih funkcija jetre u brojnim patološkim stanjima. Mehanizmi kojima gojaznost dovodi do poremećaja metaboličkih procesa u jetri su danas predmet mnogobrojnih istraživanja. Metaboličke i hormonske promene koje su posledica prevashodno visceralne gojaznosti, dovode vremenom do nagomilavanja lipida u jetri. Povećana učestalost gojaznosti i razvoj metaboličkog sindroma doprinose pojavi patofizioloških promena u jetri i razvoju nealkoholne bolesti masne jetre (NAFLD), jednoj od najčešćih bolesti jetre u zapadnoevropskim zemljama. U ovom preglednom članku razmotrili smo najnovije literaturne podatke koji se odnose na ulogu jetre u metabolizmu glukoze i lipida u stanju gojaznosti., The liver plays a vital role in metabolic homeostasis and represents a major site for complex regulation of substrates (carbohydrates, lipids, and proteins) by insulin and other hormones. The significance of liver metabolic functions in many pathophysiological conditions is highlighted over the past decades. Mechanisms of obesity-induced metabolic disturbance in the liver are the topic of numerous research studies. Metabolic and hormonal changes which are caused primarily by visceral obesity lead to hepatic lipid accumulation. Increased prevalence of obesity and the development of metabolic syndrome contribute to pathophysiological changes in the liver and development of non-alcoholic fatty liver disease (NAFLD), one of the most common diseases in Western societies. In this review, we discussed most recent literature data related to the role of the liver in glucose and lipid metabolism in obesity.",
journal = "Medicinska istraživanja",
title = "Uloga jetre u metabolizmu glukoze i lipida u stanju gojaznosti, The role of the liver in glucose and lipid metabolism in obesity",
volume = "52",
number = "3",
pages = "1-6",
doi = "10.5937/MedIst1803001S"
}

Stanimirović, J., Obradović, M. M., Gluvić, Z.,& Isenović, E. R.. (2018). Uloga jetre u metabolizmu glukoze i lipida u stanju gojaznosti. in Medicinska istraživanja, 52(3), 1-6.
https://doi.org/10.5937/MedIst1803001S

Stanimirović J, Obradović MM, Gluvić Z, Isenović ER. Uloga jetre u metabolizmu glukoze i lipida u stanju gojaznosti. in Medicinska istraživanja. 2018;52(3):1-6.
doi:10.5937/MedIst1803001S .

Stanimirović, Julijana, Obradović, Milan M., Gluvić, Zoran, Isenović, Esma R., "Uloga jetre u metabolizmu glukoze i lipida u stanju gojaznosti" in Medicinska istraživanja, 52, no. 3 (2018):1-6,
https://doi.org/10.5937/MedIst1803001S . .

TY  - JOUR
AU  - Kovačević, Pejka
AU  - Gluvić, Zoran
AU  - Putniković, Biljana
AU  - Zarić, Božidarka
AU  - Radenković, Saša
AU  - Resanović, Ivana
AU  - Isenović, Esma R.
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10155
AB  - This study aims to examine the influence of admission glycaemia and glycosylated haemoglobin (HbA1C) levels on the length of hospitalization and its outcome in insulin-independent diabetes mellitus (DM) patients suffering from ST-Segment Elevation Myocardial Infarction (STEMI)/Non-STEMI (NSTEMI). This cross-sectional study included 103 subjects with a history of insulin-independent DM, currently hospitalized due to acute myocardial infarction (AMI). Out of 103 subjects, 59 (57%) were men and 66 (64.1%) of them suffered from STEMI. Mean age of study population was 67±9 years. The following parameters were monitored: demographic, coronary, cardiovascular and DM risk factors history, as well as laboratory, clinical, echocardiography and angiography parameters. DM mean duration was 7 (1-30) months, and it influenced the length of hospitalization (r=0.232, p<0.05), but not the outcome (r=0.174, p>0.05). Mean length of hospitalization was 8 and 8.5 days in STEMI and NSTEMI patients respectively, with no difference between groups (log-rank ch2= 0.476, p>0.05). HbA1C values influenced the length of hospitalization (r=0.213, p<0.05), opposite to admission glycaemia (r=0.148, p>0.05). Duration of DM and the level of HbA1C prolong the length of hospitalization, but do not influence the clinical outcome of AMI patients suffering from insulin-independent DM.
AB  - Cilj prikazane studije je izučavanje uticaja glikemije i glikoziliranog hemoglobina (HbA1C) pri prijemu u bolnicu na dužinu trajanja hospitalizacije, kao i njen ishod kod kod obolelih od insulin-nezavisnog dijabetesa sa NSTEMI/STEMI. Materijal i metode: Ova studija je uključila 103 ispitanika, od kojih su 59 (57%) ispitanici muškog pola, a 66 (64.1%) ispitanika imalo STEMI. Prosečna životna dob ispitivane populacije je bila 67±9 godina. Praćeni su sledeći parametri: demografske karakteristike, anamneza o koronarnim, kardiovaskularnim i rizičnim faktorima za dijabetes, kao i laboratorijski, klinički, ehokardiografski parametri. Rezultati: Prosečno trajanje dijabetesa kod osoba uključenih u studiju je bilo 7 (1-30) meseci i imalo je uticaj na dužinu hospitalizacije (r=0.232, p<0.05), ali ne i na njen krajnji ishod (r=0.174, p>0.05). Prosečno trajanje hospitalizacije je bilo 8 i 8.5 dana kod ispitanika sa STEMI i NSTEMI i nije se razlikovalo među grupama ispitanika (log-rank ch2= 0.476, p>0.05). Nivoi HbA1C su uticali na dužinu trajanja hospitalizacije (r=0.213, p<0.05), što nije bio slučaj sa glikemijom pri prijemu u bolnicu (r=0.148, p>0.05). Zaključak: Dužina trajanja DM i nivo HbA1C produžavaju dužinu hospitalizacije, ali ne utiču na klinički ishod ispitanika sa insulin-nezavisnim dijabetesom koji su doživeli AIM.
T2  - Medicinska istraživanja
T1  - Influence of glycaemia and HbA1C levels at admission of insulin-independent diabetes patients on the length and outcome of hospitalization due to NSTEMI/STEMI
T1  - Uticaj glikemije i nivoa HbA1C na prijemu na dužinu i ishod hospitalizacije kod obolelih od insulin-nezavisnog dijabetesa sa NSTEMI/STEMI
VL  - 52
IS  - 3
SP  - 1
EP  - 6
DO  - 10.5937/MedIst1801001K
ER  - 

@article{
author = "Kovačević, Pejka and Gluvić, Zoran and Putniković, Biljana and Zarić, Božidarka and Radenković, Saša and Resanović, Ivana and Isenović, Esma R.",
year = "2018",
abstract = "This study aims to examine the influence of admission glycaemia and glycosylated haemoglobin (HbA1C) levels on the length of hospitalization and its outcome in insulin-independent diabetes mellitus (DM) patients suffering from ST-Segment Elevation Myocardial Infarction (STEMI)/Non-STEMI (NSTEMI). This cross-sectional study included 103 subjects with a history of insulin-independent DM, currently hospitalized due to acute myocardial infarction (AMI). Out of 103 subjects, 59 (57%) were men and 66 (64.1%) of them suffered from STEMI. Mean age of study population was 67±9 years. The following parameters were monitored: demographic, coronary, cardiovascular and DM risk factors history, as well as laboratory, clinical, echocardiography and angiography parameters. DM mean duration was 7 (1-30) months, and it influenced the length of hospitalization (r=0.232, p<0.05), but not the outcome (r=0.174, p>0.05). Mean length of hospitalization was 8 and 8.5 days in STEMI and NSTEMI patients respectively, with no difference between groups (log-rank ch2= 0.476, p>0.05). HbA1C values influenced the length of hospitalization (r=0.213, p<0.05), opposite to admission glycaemia (r=0.148, p>0.05). Duration of DM and the level of HbA1C prolong the length of hospitalization, but do not influence the clinical outcome of AMI patients suffering from insulin-independent DM., Cilj prikazane studije je izučavanje uticaja glikemije i glikoziliranog hemoglobina (HbA1C) pri prijemu u bolnicu na dužinu trajanja hospitalizacije, kao i njen ishod kod kod obolelih od insulin-nezavisnog dijabetesa sa NSTEMI/STEMI. Materijal i metode: Ova studija je uključila 103 ispitanika, od kojih su 59 (57%) ispitanici muškog pola, a 66 (64.1%) ispitanika imalo STEMI. Prosečna životna dob ispitivane populacije je bila 67±9 godina. Praćeni su sledeći parametri: demografske karakteristike, anamneza o koronarnim, kardiovaskularnim i rizičnim faktorima za dijabetes, kao i laboratorijski, klinički, ehokardiografski parametri. Rezultati: Prosečno trajanje dijabetesa kod osoba uključenih u studiju je bilo 7 (1-30) meseci i imalo je uticaj na dužinu hospitalizacije (r=0.232, p<0.05), ali ne i na njen krajnji ishod (r=0.174, p>0.05). Prosečno trajanje hospitalizacije je bilo 8 i 8.5 dana kod ispitanika sa STEMI i NSTEMI i nije se razlikovalo među grupama ispitanika (log-rank ch2= 0.476, p>0.05). Nivoi HbA1C su uticali na dužinu trajanja hospitalizacije (r=0.213, p<0.05), što nije bio slučaj sa glikemijom pri prijemu u bolnicu (r=0.148, p>0.05). Zaključak: Dužina trajanja DM i nivo HbA1C produžavaju dužinu hospitalizacije, ali ne utiču na klinički ishod ispitanika sa insulin-nezavisnim dijabetesom koji su doživeli AIM.",
journal = "Medicinska istraživanja",
title = "Influence of glycaemia and HbA1C levels at admission of insulin-independent diabetes patients on the length and outcome of hospitalization due to NSTEMI/STEMI, Uticaj glikemije i nivoa HbA1C na prijemu na dužinu i ishod hospitalizacije kod obolelih od insulin-nezavisnog dijabetesa sa NSTEMI/STEMI",
volume = "52",
number = "3",
pages = "1-6",
doi = "10.5937/MedIst1801001K"
}

Kovačević, P., Gluvić, Z., Putniković, B., Zarić, B., Radenković, S., Resanović, I.,& Isenović, E. R.. (2018). Influence of glycaemia and HbA1C levels at admission of insulin-independent diabetes patients on the length and outcome of hospitalization due to NSTEMI/STEMI. in Medicinska istraživanja, 52(3), 1-6.
https://doi.org/10.5937/MedIst1801001K

Kovačević P, Gluvić Z, Putniković B, Zarić B, Radenković S, Resanović I, Isenović ER. Influence of glycaemia and HbA1C levels at admission of insulin-independent diabetes patients on the length and outcome of hospitalization due to NSTEMI/STEMI. in Medicinska istraživanja. 2018;52(3):1-6.
doi:10.5937/MedIst1801001K .

Kovačević, Pejka, Gluvić, Zoran, Putniković, Biljana, Zarić, Božidarka, Radenković, Saša, Resanović, Ivana, Isenović, Esma R., "Influence of glycaemia and HbA1C levels at admission of insulin-independent diabetes patients on the length and outcome of hospitalization due to NSTEMI/STEMI" in Medicinska istraživanja, 52, no. 3 (2018):1-6,
https://doi.org/10.5937/MedIst1801001K . .

TY  - CHAP
AU  - Obradović, Milan M.
AU  - Zarić, Božidarka
AU  - Sudar-Milovanović, Emina
AU  - Perović, Milan
AU  - Resanović, Ivana
AU  - Gluvić, Zoran
AU  - Isenović, Esma R.
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8014
AB  - Nitric oxide (NO) is a free radical which, in reactions with various molecules causes multiple biological effects. NO is exceptionally regulated and extends to almost every cell type and function within circulation. Generation and actions of NO are regulated by various hormones under physiological and pathophysiological conditions. Nitric oxide synthases (NOS) are the enzymes responsible for NO generation. In mammals, neuronal NOS (nNOS) and endothelial NOS (eNOS) are constitutively expressed, while inducible NOS (iNOS) mediate in immune defense. Altered NO level is associated with obesity, insulin resistance (IR), diabetes and cardiovascular diseases (CVD). Disturbances in eNOS and iNOS regulation accompany multiple changes in endothelial function and contribute to development of CVD. Furthermore, key step in initiation and progression of atherosclerosis is reduction in bioactivity of endothelial cell-derived NO. Here we shall focus on recent literature data related to the role of eNOS and iNOS in physiological and pathophysiological conditions. © 2018 Nova Science Publishers, Inc. All rights reserved.
PB  - Nova Science Publishers
T2  - Horizons in World Cardiovascular Research
T1  - The role of eNOS and iNOS in pathophysiological conditions
VL  - 15
SP  - 65
EP  - 102
UR  - https://hdl.handle.net/21.15107/rcub_vinar_8014
ER  - 

@inbook{
author = "Obradović, Milan M. and Zarić, Božidarka and Sudar-Milovanović, Emina and Perović, Milan and Resanović, Ivana and Gluvić, Zoran and Isenović, Esma R.",
year = "2018",
abstract = "Nitric oxide (NO) is a free radical which, in reactions with various molecules causes multiple biological effects. NO is exceptionally regulated and extends to almost every cell type and function within circulation. Generation and actions of NO are regulated by various hormones under physiological and pathophysiological conditions. Nitric oxide synthases (NOS) are the enzymes responsible for NO generation. In mammals, neuronal NOS (nNOS) and endothelial NOS (eNOS) are constitutively expressed, while inducible NOS (iNOS) mediate in immune defense. Altered NO level is associated with obesity, insulin resistance (IR), diabetes and cardiovascular diseases (CVD). Disturbances in eNOS and iNOS regulation accompany multiple changes in endothelial function and contribute to development of CVD. Furthermore, key step in initiation and progression of atherosclerosis is reduction in bioactivity of endothelial cell-derived NO. Here we shall focus on recent literature data related to the role of eNOS and iNOS in physiological and pathophysiological conditions. © 2018 Nova Science Publishers, Inc. All rights reserved.",
publisher = "Nova Science Publishers",
journal = "Horizons in World Cardiovascular Research",
booktitle = "The role of eNOS and iNOS in pathophysiological conditions",
volume = "15",
pages = "65-102",
url = "https://hdl.handle.net/21.15107/rcub_vinar_8014"
}

Obradović, M. M., Zarić, B., Sudar-Milovanović, E., Perović, M., Resanović, I., Gluvić, Z.,& Isenović, E. R.. (2018). The role of eNOS and iNOS in pathophysiological conditions. in Horizons in World Cardiovascular Research
Nova Science Publishers., 15, 65-102.
https://hdl.handle.net/21.15107/rcub_vinar_8014

Obradović MM, Zarić B, Sudar-Milovanović E, Perović M, Resanović I, Gluvić Z, Isenović ER. The role of eNOS and iNOS in pathophysiological conditions. in Horizons in World Cardiovascular Research. 2018;15:65-102.
https://hdl.handle.net/21.15107/rcub_vinar_8014 .

Obradović, Milan M., Zarić, Božidarka, Sudar-Milovanović, Emina, Perović, Milan, Resanović, Ivana, Gluvić, Zoran, Isenović, Esma R., "The role of eNOS and iNOS in pathophysiological conditions" in Horizons in World Cardiovascular Research, 15 (2018):65-102,
https://hdl.handle.net/21.15107/rcub_vinar_8014 .

TY  - JOUR
AU  - Gluvić, Zoran
AU  - Zarić, Božidarka
AU  - Resanović, Ivana
AU  - Obradović, Milan M.
AU  - Mitrović, Aleksandar
AU  - Radak, Đorđe J.
AU  - Isenović, Esma R.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1470
AB  - Metabolic syndrome (MetS) is a leading public health and clinical challenge worldwide. MetS represents a group of interrelated risk factors that predict cardiovascular diseases (CVD) and diabetes mellitus (DM). Its prevalence ranges between 10 and 84%, depending on the geographic region, urban or rural environment, individual demographic characteristics of the population studied (sex, age, racial and ethnic origin), as well as the criteria used to define MetS. Persons with MetS have higher mortality rate when compared with people without MetS, primarily caused by progressive atherosclerosis, accelerated by pro-inflammatory and pro-coagulation components of MetS. Considering the high prevalence of metabolic disorders (glucose metabolism disorder, hypertension, dyslipidaemia, obesity etc.), preventive healthcare should focus on changing lifestyle in order to reduce obesity and increase physical activity. This narrative review considers the available evidence from clinical and experimental studies dealing with MetS, and current treatment options for patients with insulin resistance and MetS.
T2  - Current Vascular Pharmacology
T1  - Link between Metabolic Syndrome and Insulin Resistance
VL  - 15
IS  - 1
SP  - 30
EP  - 39
DO  - 10.2174/1570161114666161007164510
ER  - 

@article{
author = "Gluvić, Zoran and Zarić, Božidarka and Resanović, Ivana and Obradović, Milan M. and Mitrović, Aleksandar and Radak, Đorđe J. and Isenović, Esma R.",
year = "2017",
abstract = "Metabolic syndrome (MetS) is a leading public health and clinical challenge worldwide. MetS represents a group of interrelated risk factors that predict cardiovascular diseases (CVD) and diabetes mellitus (DM). Its prevalence ranges between 10 and 84%, depending on the geographic region, urban or rural environment, individual demographic characteristics of the population studied (sex, age, racial and ethnic origin), as well as the criteria used to define MetS. Persons with MetS have higher mortality rate when compared with people without MetS, primarily caused by progressive atherosclerosis, accelerated by pro-inflammatory and pro-coagulation components of MetS. Considering the high prevalence of metabolic disorders (glucose metabolism disorder, hypertension, dyslipidaemia, obesity etc.), preventive healthcare should focus on changing lifestyle in order to reduce obesity and increase physical activity. This narrative review considers the available evidence from clinical and experimental studies dealing with MetS, and current treatment options for patients with insulin resistance and MetS.",
journal = "Current Vascular Pharmacology",
title = "Link between Metabolic Syndrome and Insulin Resistance",
volume = "15",
number = "1",
pages = "30-39",
doi = "10.2174/1570161114666161007164510"
}

Gluvić, Z., Zarić, B., Resanović, I., Obradović, M. M., Mitrović, A., Radak, Đ. J.,& Isenović, E. R.. (2017). Link between Metabolic Syndrome and Insulin Resistance. in Current Vascular Pharmacology, 15(1), 30-39.
https://doi.org/10.2174/1570161114666161007164510

Gluvić Z, Zarić B, Resanović I, Obradović MM, Mitrović A, Radak ĐJ, Isenović ER. Link between Metabolic Syndrome and Insulin Resistance. in Current Vascular Pharmacology. 2017;15(1):30-39.
doi:10.2174/1570161114666161007164510 .

Gluvić, Zoran, Zarić, Božidarka, Resanović, Ivana, Obradović, Milan M., Mitrović, Aleksandar, Radak, Đorđe J., Isenović, Esma R., "Link between Metabolic Syndrome and Insulin Resistance" in Current Vascular Pharmacology, 15, no. 1 (2017):30-39,
https://doi.org/10.2174/1570161114666161007164510 . .

TY  - JOUR
AU  - Obradović, Milica
AU  - Gluvić, Zoran
AU  - Petrović, Nina
AU  - Obradović, Milan M.
AU  - Tomasevic, Ratko
AU  - Dugalic, Predrag
AU  - Isenović, Esma R.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1700
AB  - Introduction. Chronic liver diseases (CLD) are an important cause of morbidity and mortality in general population. The aim of this study was to analyze potential differences between patients with CLD and healthy control group, and to estimate the severity of CLD by using simple questionnaires: general health questionnaire (GHQ-12) and chronic liver disease questionnaire (CLDQ). Methods. A cross-sectional pilot study was performed in Zemun Clinical Hospital during years 2014 and 2015. Sixty participants were divided into 4 groups (15 per group): chronic alcoholic hepatitis, other chronic hepatitis, liver cirrhosis, and healthy control group. Entire study population chose one of four offered answers of structured questionnaires GHQ-12 and CLDQ, based on which mean model of end-stage liver disease (MELD) and Child-Turcotte-Pugh (CTP) scores were calculated. Results. Mean GHQ12 and CLDQ scores were 10.5 and 5.21 +/- 1.11 respectively. Regarding certain CLDQ domain scores, a significant difference between alcoholic and non-alcoholic hepatitis groups in the worry domain was observed. Mean MELD score was 7.42 +/- 2.89 and did not differ between chronic hepatitis groups, while mean CTP score was 5.73 +/- 0.88. A statistically significant correlation was observed between GHQ12 and CLDQ scores (rho = -0.404, p LT 0.01), but not between subjective and objective scores. Conclusions. Mean GHQ12 and CLDQ scores pointed out to general psychological no-distress condition of the studied participants, as well as scarcely expressed CLD-specific complaints. Mean MELD and CTP scores indicated stable chronic liver diseases, with low three-month mortality rates in the cases of chronic hepatitis, as well as determination to Child A group in the case of liver cirrhosis.
T2  - Romanian Journal of Internal Medicine
T1  - A quality of life assessment and the correlation between generic and disease-specific questionnaires scores in outpatients with chronic liver disease-pilot study
VL  - 55
IS  - 3
SP  - 129
EP  - 137
DO  - 10.1515/rjim-2017-0014
ER  - 

@article{
author = "Obradović, Milica and Gluvić, Zoran and Petrović, Nina and Obradović, Milan M. and Tomasevic, Ratko and Dugalic, Predrag and Isenović, Esma R.",
year = "2017",
abstract = "Introduction. Chronic liver diseases (CLD) are an important cause of morbidity and mortality in general population. The aim of this study was to analyze potential differences between patients with CLD and healthy control group, and to estimate the severity of CLD by using simple questionnaires: general health questionnaire (GHQ-12) and chronic liver disease questionnaire (CLDQ). Methods. A cross-sectional pilot study was performed in Zemun Clinical Hospital during years 2014 and 2015. Sixty participants were divided into 4 groups (15 per group): chronic alcoholic hepatitis, other chronic hepatitis, liver cirrhosis, and healthy control group. Entire study population chose one of four offered answers of structured questionnaires GHQ-12 and CLDQ, based on which mean model of end-stage liver disease (MELD) and Child-Turcotte-Pugh (CTP) scores were calculated. Results. Mean GHQ12 and CLDQ scores were 10.5 and 5.21 +/- 1.11 respectively. Regarding certain CLDQ domain scores, a significant difference between alcoholic and non-alcoholic hepatitis groups in the worry domain was observed. Mean MELD score was 7.42 +/- 2.89 and did not differ between chronic hepatitis groups, while mean CTP score was 5.73 +/- 0.88. A statistically significant correlation was observed between GHQ12 and CLDQ scores (rho = -0.404, p LT 0.01), but not between subjective and objective scores. Conclusions. Mean GHQ12 and CLDQ scores pointed out to general psychological no-distress condition of the studied participants, as well as scarcely expressed CLD-specific complaints. Mean MELD and CTP scores indicated stable chronic liver diseases, with low three-month mortality rates in the cases of chronic hepatitis, as well as determination to Child A group in the case of liver cirrhosis.",
journal = "Romanian Journal of Internal Medicine",
title = "A quality of life assessment and the correlation between generic and disease-specific questionnaires scores in outpatients with chronic liver disease-pilot study",
volume = "55",
number = "3",
pages = "129-137",
doi = "10.1515/rjim-2017-0014"
}

Obradović, M., Gluvić, Z., Petrović, N., Obradović, M. M., Tomasevic, R., Dugalic, P.,& Isenović, E. R.. (2017). A quality of life assessment and the correlation between generic and disease-specific questionnaires scores in outpatients with chronic liver disease-pilot study. in Romanian Journal of Internal Medicine, 55(3), 129-137.
https://doi.org/10.1515/rjim-2017-0014

Obradović M, Gluvić Z, Petrović N, Obradović MM, Tomasevic R, Dugalic P, Isenović ER. A quality of life assessment and the correlation between generic and disease-specific questionnaires scores in outpatients with chronic liver disease-pilot study. in Romanian Journal of Internal Medicine. 2017;55(3):129-137.
doi:10.1515/rjim-2017-0014 .

Obradović, Milica, Gluvić, Zoran, Petrović, Nina, Obradović, Milan M., Tomasevic, Ratko, Dugalic, Predrag, Isenović, Esma R., "A quality of life assessment and the correlation between generic and disease-specific questionnaires scores in outpatients with chronic liver disease-pilot study" in Romanian Journal of Internal Medicine, 55, no. 3 (2017):129-137,
https://doi.org/10.1515/rjim-2017-0014 . .

TY  - JOUR
AU  - Popin-Tarić, Marija
AU  - Gluvić, Zoran
AU  - Mitrović, Bojan
AU  - Samardžić, Vladimir
AU  - Lačković, Milena
AU  - Vasić-Vlaisavljević, Anita
AU  - Stanojević, Aleksandar
AU  - Kulić, Adrijana
AU  - Libek, Vesna
AU  - Resanović, Ivana
AU  - Isenović, Esma R.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10156
AB  - U okviru ovog rada prikazan je slučaj bolesnika sa komplikovanim akutnim dislipidemijskim pankreatitisom u čijem je zbrinjavanju učestvovao tim, koji su činili endokrinolozi, gastroenterolozi i transfuziolozi. Dislipidemija, prevashodno tip IV dislipidemije, predstavlja čest uzrok nastanka akutnog pankreatitisa u populaciji mladih ljudi, posebno u slučajevima nezadovoljavajuće komplijanse (neredovno uzimanje preporučenih fibrata i nepridržavanje higijensko-dijetetskog režima). Tretman akutnog pankreatitisa se nezavisno od etiologije, zbog težine stanja, kompleksnosti lečenja i monitoringa bolesnika, sprovodi u Jedinicama intenzivnog lečenja. U slučajevima kada je dislipidemija uzrok akutnog pankreatitisa, često se u sklopu akutnog zbrinjavanja sprovodi i terapijska izmena plazme, kojom se brzo i značajno koriguju nivoi lipida, prevashodno triglicerida. Terapijska izmena plazme zahteva aktivnost transfuzioloških ekipa, koje su u manjim centrima, često nedostupne.
AB  - This article presents a case of patient with acute and complicated dyslipidaemic pancreatitis, managed by team, consisted of the endocrinologists, gastroenterologists and transfusiologists. Dyslipidaemia, predominantly type IV, is a common cause of acute pancreatitis in young patients, especially in the cases of poor compliance (irregular taking of recommended fibrates and failure to comply with the dietary regime). The treatment of acute pancreatitis, regardless of the aetiology, is due to the severity of the condition, the complexity of the treatment, and the monitoring of patients, in the Intensive Care Units. In cases where dyslipidaemia is the cause of acute pancreatitis, in the context of acute care, a therapeutic plasma exchange is often performed. It rapidly and significantly corrects lipid levels, primarily triglycerides. Therapeutic plasma exchange requires the activity of transfusiology team, which are often unavailable in smaller hospitals.
T2  - Materia medica
T1  - Prikaz timskog zbrinjavanja obolelog od akutnog teškog dislipidemijskog pankreatitisa - iskustvo jednog tercijernog zdravstvenog centra
T1  - The team management of patient suffered of acute severe dyslipidaemic pancreatitis: The experience of one tertiary health centre
VL  - 33
IS  - 3
SP  - 1557
EP  - 1562
DO  - 10.5937/MatMed1703557P
ER  - 

@article{
author = "Popin-Tarić, Marija and Gluvić, Zoran and Mitrović, Bojan and Samardžić, Vladimir and Lačković, Milena and Vasić-Vlaisavljević, Anita and Stanojević, Aleksandar and Kulić, Adrijana and Libek, Vesna and Resanović, Ivana and Isenović, Esma R.",
year = "2017",
abstract = "U okviru ovog rada prikazan je slučaj bolesnika sa komplikovanim akutnim dislipidemijskim pankreatitisom u čijem je zbrinjavanju učestvovao tim, koji su činili endokrinolozi, gastroenterolozi i transfuziolozi. Dislipidemija, prevashodno tip IV dislipidemije, predstavlja čest uzrok nastanka akutnog pankreatitisa u populaciji mladih ljudi, posebno u slučajevima nezadovoljavajuće komplijanse (neredovno uzimanje preporučenih fibrata i nepridržavanje higijensko-dijetetskog režima). Tretman akutnog pankreatitisa se nezavisno od etiologije, zbog težine stanja, kompleksnosti lečenja i monitoringa bolesnika, sprovodi u Jedinicama intenzivnog lečenja. U slučajevima kada je dislipidemija uzrok akutnog pankreatitisa, često se u sklopu akutnog zbrinjavanja sprovodi i terapijska izmena plazme, kojom se brzo i značajno koriguju nivoi lipida, prevashodno triglicerida. Terapijska izmena plazme zahteva aktivnost transfuzioloških ekipa, koje su u manjim centrima, često nedostupne., This article presents a case of patient with acute and complicated dyslipidaemic pancreatitis, managed by team, consisted of the endocrinologists, gastroenterologists and transfusiologists. Dyslipidaemia, predominantly type IV, is a common cause of acute pancreatitis in young patients, especially in the cases of poor compliance (irregular taking of recommended fibrates and failure to comply with the dietary regime). The treatment of acute pancreatitis, regardless of the aetiology, is due to the severity of the condition, the complexity of the treatment, and the monitoring of patients, in the Intensive Care Units. In cases where dyslipidaemia is the cause of acute pancreatitis, in the context of acute care, a therapeutic plasma exchange is often performed. It rapidly and significantly corrects lipid levels, primarily triglycerides. Therapeutic plasma exchange requires the activity of transfusiology team, which are often unavailable in smaller hospitals.",
journal = "Materia medica",
title = "Prikaz timskog zbrinjavanja obolelog od akutnog teškog dislipidemijskog pankreatitisa - iskustvo jednog tercijernog zdravstvenog centra, The team management of patient suffered of acute severe dyslipidaemic pancreatitis: The experience of one tertiary health centre",
volume = "33",
number = "3",
pages = "1557-1562",
doi = "10.5937/MatMed1703557P"
}

Popin-Tarić, M., Gluvić, Z., Mitrović, B., Samardžić, V., Lačković, M., Vasić-Vlaisavljević, A., Stanojević, A., Kulić, A., Libek, V., Resanović, I.,& Isenović, E. R.. (2017). Prikaz timskog zbrinjavanja obolelog od akutnog teškog dislipidemijskog pankreatitisa - iskustvo jednog tercijernog zdravstvenog centra. in Materia medica, 33(3), 1557-1562.
https://doi.org/10.5937/MatMed1703557P

Popin-Tarić M, Gluvić Z, Mitrović B, Samardžić V, Lačković M, Vasić-Vlaisavljević A, Stanojević A, Kulić A, Libek V, Resanović I, Isenović ER. Prikaz timskog zbrinjavanja obolelog od akutnog teškog dislipidemijskog pankreatitisa - iskustvo jednog tercijernog zdravstvenog centra. in Materia medica. 2017;33(3):1557-1562.
doi:10.5937/MatMed1703557P .

Popin-Tarić, Marija, Gluvić, Zoran, Mitrović, Bojan, Samardžić, Vladimir, Lačković, Milena, Vasić-Vlaisavljević, Anita, Stanojević, Aleksandar, Kulić, Adrijana, Libek, Vesna, Resanović, Ivana, Isenović, Esma R., "Prikaz timskog zbrinjavanja obolelog od akutnog teškog dislipidemijskog pankreatitisa - iskustvo jednog tercijernog zdravstvenog centra" in Materia medica, 33, no. 3 (2017):1557-1562,
https://doi.org/10.5937/MatMed1703557P . .

TY  - JOUR
AU  - Mitrović, Bojan
AU  - Gluvić, Zoran
AU  - Obradović, Milan M.
AU  - Lačković, Milena
AU  - Samardžić, Vladimir
AU  - Ćirić, Jasmina
AU  - Isenović, Esma R.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10311
AB  - Primarni hipotireoidizam negativno utiče na kvalitet života obolelih. Poboljšanje kvaliteta života očekuje se uspostavljanjem eutireoidnog stanja primenom levotiroksina. Kvalitet života se može "proceniti" primenom različitih upitnika, poput upitnika opšteg zdravlja (GHQ12; engl. General Health Questionnaire) i tireoidno specifičnog upitnika (TSQ; engl. Thyroid Symptom Questionnaire). Ciljevi ovog rada su: sumiranje standardno i modifikovano rangiranih odgovora oba upitnika u skorove; ispitivanje postojanja razlika u apsolutnim vrednostima skorova među grupama ispitanika; svrstavanje dobijenih skorova u različite klastere (bez poremećaja, manji poremećaj, veliki poremećaj), i ispitivanje postojanja razlika u distribuciji frekvencija ispitanika među njima. Studija preseka je sprovedena u KBC Zemun i obuhvatila je 90 ispitanica, koje su bile podeljene u tri jednake grupe (30 po grupi): hipotireoidnu bez terapije, eutiroidnu sa levotiroksinom i kontrolnu, eutireoidnu grupu bez terapije. Ispitanice su zaokruživale svoj odgovor na postavljena pitanja upitnika, koji je potom rangovno transformisan pomoću dva modelastandardnog i modifikovanog, a potom zbirno sumiran. Za statističku analizu korišćen je softver SPSS for Windows 18.0. Prosečan nivo tireostimulišućeg hormona (TSH) u ispitivanoj populaciji je iznosio 1,3±0,3 (1,1-2,2) mU/L. Prosečni TSQm, TSQs, GHQm and GHQs skorovi su bili 14±7, 13±6, 11±7, i 11±6 i razlikovali su se među grupama. Najniži skorovi su registrovani u grupi levotiroksinom-tretiranih, nezavisno od modela rangiranja, pri čemu je nivo TSH ukazivao na adekvatnu supstituciju levotiroksinom. Prosečni TSQs/TSQm i GHQs/GHQm skorovi pokazuju međusobnu statističku korelaciju. Skorovi i skorom-definisani klasteri oba primenjena upitnika odgovaraju kliničkoj prezentaciji prikazanoj kroz grupe ispitivane populacije. S obzirom da se prosečni skorovi upitnika međusobno razlikuju, a da oba modela rangovne transformacije istog upitnika daju sličan skor, zaključujemo da je dovoljno koristiti po jedan upitnik iz obe kategorije instrumenata za ispitivanje kvaliteta života. Jednostavnost primene ovih upitnika, nezavisno od modela transformacije dobijenih odgovora u rangove, omogućava njihovu primenu pri započinjanju supstitucije levotiroksinom, ali takođe i proceni efikasnosti primenjene terapije.
AB  - Primary hypothyroidism negatively affects patients' quality of life. Improving the quality of life is expected by establishing eutyreoid state using levothyroxine therapy. The quality of life can be "assessed" by applying various questionnaires, such as the general health questionnaire (GHQ12) and thyroid symptom questionnaire (TSQ). The aims of present study were to: sum standard and modified-ranked answers of both questionnaires, rank the scores, test differences in the absolute values of the scores between the groups, classify obtained scores in different clusters (no distress, a minor, and major distress), and test differences in the distribution of frequencies of the respondents among them. Cross-sectional study was conducted in Zemun Clinical Hospital and it included 90 subjects. The subjects were divided into three equal groups (30 subjects per group): hypothyroid without treatment, euthyroid with levothyroxine, and control, euthyroid group without treatment. The subjects answered the questions in the questionnaire, and the answers were then transformed into the ranking of two modelsstandard and modified, and then summarized. Statistical analysis was performed using the SPSS for Windows 18.0. The average level of thyroid stimulating hormone (TSH) in the study population was 1.3 ± 0.3 (1.1-2.2) mU/L. Average TSQm, TSQs, GHQm and GHQs scores were 14±7, 13±6, 11±7 and 11±6 and differed between groups. The lowest scores were registered in the group of levothyroxine-treated, regardless of the ranking models, with the level of TSH that indicates an adequate substitution levothyroxine. Average TSQs/TSQm and GHQs/GHQm scores show a statistical correlation with each other. Scores and scores-defined clusters of both questionnaires are appropriate for clinical presentation shown by specific groups of the population. Considering that the average scores of the questionnaire differ from each other, and that both models rank-transformation of the same questionnaire give a similar score, it is sufficient to use one questionnaire from both categories of instruments for testing the quality of life. The ease of applying these questionnaires, independent of the transformation obtained in response ranges and their application when starting levothyroxine substitution, were used to assess the effectiveness of the therapy.
T2  - Medicinska istraživanja
T1  - Ispitivanje kvaliteta života obolelih od primarne hipotireoze primenom različitih upitnika i metoda njihove obrade
T1  - Primary hypothyroidism quality of life assessment by application of different questionnaires and its different processing
VL  - 50
IS  - 2
SP  - 1
EP  - 6
DO  - 10.5937/MedIst1602001M
ER  - 

@article{
author = "Mitrović, Bojan and Gluvić, Zoran and Obradović, Milan M. and Lačković, Milena and Samardžić, Vladimir and Ćirić, Jasmina and Isenović, Esma R.",
year = "2016",
abstract = "Primarni hipotireoidizam negativno utiče na kvalitet života obolelih. Poboljšanje kvaliteta života očekuje se uspostavljanjem eutireoidnog stanja primenom levotiroksina. Kvalitet života se može "proceniti" primenom različitih upitnika, poput upitnika opšteg zdravlja (GHQ12; engl. General Health Questionnaire) i tireoidno specifičnog upitnika (TSQ; engl. Thyroid Symptom Questionnaire). Ciljevi ovog rada su: sumiranje standardno i modifikovano rangiranih odgovora oba upitnika u skorove; ispitivanje postojanja razlika u apsolutnim vrednostima skorova među grupama ispitanika; svrstavanje dobijenih skorova u različite klastere (bez poremećaja, manji poremećaj, veliki poremećaj), i ispitivanje postojanja razlika u distribuciji frekvencija ispitanika među njima. Studija preseka je sprovedena u KBC Zemun i obuhvatila je 90 ispitanica, koje su bile podeljene u tri jednake grupe (30 po grupi): hipotireoidnu bez terapije, eutiroidnu sa levotiroksinom i kontrolnu, eutireoidnu grupu bez terapije. Ispitanice su zaokruživale svoj odgovor na postavljena pitanja upitnika, koji je potom rangovno transformisan pomoću dva modelastandardnog i modifikovanog, a potom zbirno sumiran. Za statističku analizu korišćen je softver SPSS for Windows 18.0. Prosečan nivo tireostimulišućeg hormona (TSH) u ispitivanoj populaciji je iznosio 1,3±0,3 (1,1-2,2) mU/L. Prosečni TSQm, TSQs, GHQm and GHQs skorovi su bili 14±7, 13±6, 11±7, i 11±6 i razlikovali su se među grupama. Najniži skorovi su registrovani u grupi levotiroksinom-tretiranih, nezavisno od modela rangiranja, pri čemu je nivo TSH ukazivao na adekvatnu supstituciju levotiroksinom. Prosečni TSQs/TSQm i GHQs/GHQm skorovi pokazuju međusobnu statističku korelaciju. Skorovi i skorom-definisani klasteri oba primenjena upitnika odgovaraju kliničkoj prezentaciji prikazanoj kroz grupe ispitivane populacije. S obzirom da se prosečni skorovi upitnika međusobno razlikuju, a da oba modela rangovne transformacije istog upitnika daju sličan skor, zaključujemo da je dovoljno koristiti po jedan upitnik iz obe kategorije instrumenata za ispitivanje kvaliteta života. Jednostavnost primene ovih upitnika, nezavisno od modela transformacije dobijenih odgovora u rangove, omogućava njihovu primenu pri započinjanju supstitucije levotiroksinom, ali takođe i proceni efikasnosti primenjene terapije., Primary hypothyroidism negatively affects patients' quality of life. Improving the quality of life is expected by establishing eutyreoid state using levothyroxine therapy. The quality of life can be "assessed" by applying various questionnaires, such as the general health questionnaire (GHQ12) and thyroid symptom questionnaire (TSQ). The aims of present study were to: sum standard and modified-ranked answers of both questionnaires, rank the scores, test differences in the absolute values of the scores between the groups, classify obtained scores in different clusters (no distress, a minor, and major distress), and test differences in the distribution of frequencies of the respondents among them. Cross-sectional study was conducted in Zemun Clinical Hospital and it included 90 subjects. The subjects were divided into three equal groups (30 subjects per group): hypothyroid without treatment, euthyroid with levothyroxine, and control, euthyroid group without treatment. The subjects answered the questions in the questionnaire, and the answers were then transformed into the ranking of two modelsstandard and modified, and then summarized. Statistical analysis was performed using the SPSS for Windows 18.0. The average level of thyroid stimulating hormone (TSH) in the study population was 1.3 ± 0.3 (1.1-2.2) mU/L. Average TSQm, TSQs, GHQm and GHQs scores were 14±7, 13±6, 11±7 and 11±6 and differed between groups. The lowest scores were registered in the group of levothyroxine-treated, regardless of the ranking models, with the level of TSH that indicates an adequate substitution levothyroxine. Average TSQs/TSQm and GHQs/GHQm scores show a statistical correlation with each other. Scores and scores-defined clusters of both questionnaires are appropriate for clinical presentation shown by specific groups of the population. Considering that the average scores of the questionnaire differ from each other, and that both models rank-transformation of the same questionnaire give a similar score, it is sufficient to use one questionnaire from both categories of instruments for testing the quality of life. The ease of applying these questionnaires, independent of the transformation obtained in response ranges and their application when starting levothyroxine substitution, were used to assess the effectiveness of the therapy.",
journal = "Medicinska istraživanja",
title = "Ispitivanje kvaliteta života obolelih od primarne hipotireoze primenom različitih upitnika i metoda njihove obrade, Primary hypothyroidism quality of life assessment by application of different questionnaires and its different processing",
volume = "50",
number = "2",
pages = "1-6",
doi = "10.5937/MedIst1602001M"
}

Mitrović, B., Gluvić, Z., Obradović, M. M., Lačković, M., Samardžić, V., Ćirić, J.,& Isenović, E. R.. (2016). Ispitivanje kvaliteta života obolelih od primarne hipotireoze primenom različitih upitnika i metoda njihove obrade. in Medicinska istraživanja, 50(2), 1-6.
https://doi.org/10.5937/MedIst1602001M

Mitrović B, Gluvić Z, Obradović MM, Lačković M, Samardžić V, Ćirić J, Isenović ER. Ispitivanje kvaliteta života obolelih od primarne hipotireoze primenom različitih upitnika i metoda njihove obrade. in Medicinska istraživanja. 2016;50(2):1-6.
doi:10.5937/MedIst1602001M .

Mitrović, Bojan, Gluvić, Zoran, Obradović, Milan M., Lačković, Milena, Samardžić, Vladimir, Ćirić, Jasmina, Isenović, Esma R., "Ispitivanje kvaliteta života obolelih od primarne hipotireoze primenom različitih upitnika i metoda njihove obrade" in Medicinska istraživanja, 50, no. 2 (2016):1-6,
https://doi.org/10.5937/MedIst1602001M . .

TY  - JOUR
AU  - Mitrović, Bojan
AU  - Gluvić, Zoran
AU  - Samardžić, Vladimir
AU  - Obradović, Milan M.
AU  - Lačković, Milena
AU  - Cvetković, Zorica
AU  - Pavlović, Aleksandar
AU  - Isenović, Esma R.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10310
AB  - Tromboza portne vene (TPV) je retko oboljenje splanhničke cirkulacije, koje najčešće nastaje sadejstvom više lokalnih i/ili sistemskih faktora. Ukoliko TPV komplikuje osnovnu bolest, ona pogoršava njenu prognozu, a konkomitantno se leče obe. Iako se najčešće javlja u sklopu ciroze jetre, malignih bolesti abdominalnih organa i nekih hemopatija, postoji i idiopatska TPV, koja se definiše ekskluzijom svih poznatih uzroka TPV. U ovom radu je prikazan slučaj hronične idioptaske TPV.
AB  - Portal vein thrombosis (PVT) is a rare disorder of splanchnic circulation, frequently caused by concomitant presence of local and/or systemic factors. When portal vein thrombosis complicates causative diseases, it will worsen their prognosis, and in such a case, the causative disease and PVT are treated concomitantly. Despite the fact that PVT frequently complicates liver cirrhosis, intraabdominal malignancies, and some hematological diseases, after all causes are excluded, one can define idiopathic portal vein thrombosis. In this study we have described the case of idiopathic chronical portal vein thrombosis.
T2  - Medicinska istraživanja
T1  - Hronična idiopatska Tromboza portne vene - prikaz slučaja
T1  - Chronic idiopathic portal vein thrombosis: A case study
VL  - 50
IS  - 2
SP  - 13
EP  - 17
DO  - 10.5937/MedIst1602013M
ER  - 

@article{
author = "Mitrović, Bojan and Gluvić, Zoran and Samardžić, Vladimir and Obradović, Milan M. and Lačković, Milena and Cvetković, Zorica and Pavlović, Aleksandar and Isenović, Esma R.",
year = "2016",
abstract = "Tromboza portne vene (TPV) je retko oboljenje splanhničke cirkulacije, koje najčešće nastaje sadejstvom više lokalnih i/ili sistemskih faktora. Ukoliko TPV komplikuje osnovnu bolest, ona pogoršava njenu prognozu, a konkomitantno se leče obe. Iako se najčešće javlja u sklopu ciroze jetre, malignih bolesti abdominalnih organa i nekih hemopatija, postoji i idiopatska TPV, koja se definiše ekskluzijom svih poznatih uzroka TPV. U ovom radu je prikazan slučaj hronične idioptaske TPV., Portal vein thrombosis (PVT) is a rare disorder of splanchnic circulation, frequently caused by concomitant presence of local and/or systemic factors. When portal vein thrombosis complicates causative diseases, it will worsen their prognosis, and in such a case, the causative disease and PVT are treated concomitantly. Despite the fact that PVT frequently complicates liver cirrhosis, intraabdominal malignancies, and some hematological diseases, after all causes are excluded, one can define idiopathic portal vein thrombosis. In this study we have described the case of idiopathic chronical portal vein thrombosis.",
journal = "Medicinska istraživanja",
title = "Hronična idiopatska Tromboza portne vene - prikaz slučaja, Chronic idiopathic portal vein thrombosis: A case study",
volume = "50",
number = "2",
pages = "13-17",
doi = "10.5937/MedIst1602013M"
}

Mitrović, B., Gluvić, Z., Samardžić, V., Obradović, M. M., Lačković, M., Cvetković, Z., Pavlović, A.,& Isenović, E. R.. (2016). Hronična idiopatska Tromboza portne vene - prikaz slučaja. in Medicinska istraživanja, 50(2), 13-17.
https://doi.org/10.5937/MedIst1602013M

Mitrović B, Gluvić Z, Samardžić V, Obradović MM, Lačković M, Cvetković Z, Pavlović A, Isenović ER. Hronična idiopatska Tromboza portne vene - prikaz slučaja. in Medicinska istraživanja. 2016;50(2):13-17.
doi:10.5937/MedIst1602013M .

Mitrović, Bojan, Gluvić, Zoran, Samardžić, Vladimir, Obradović, Milan M., Lačković, Milena, Cvetković, Zorica, Pavlović, Aleksandar, Isenović, Esma R., "Hronična idiopatska Tromboza portne vene - prikaz slučaja" in Medicinska istraživanja, 50, no. 2 (2016):13-17,
https://doi.org/10.5937/MedIst1602013M . .